Split (1)

train · 22k rows

Record stringlengths 1 197k
Putting together these data will allow to correlate clinical and radiological response to QOL and NC. conditions: Glioblastoma Multiforme conditions: Relapse studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 120 type: ESTIMATED name: IA Carboplatin + IA Caelyx name: IA Carboplatin + IA Etoposide Phosphate measure: Tumor Response on MRI using the RANO Criteria measure: Progression-free Survival measure: Median overall survival measure: Treatment-related toxicity measure: Per treatment quality of life assessment measure: Incidence of treatment related Neurocognitive decline sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHUS status: RECRUITING city: Sherbrooke state: Quebec zip: J1H 5N4 country: Canada name: David Fortin, MD role: CONTACT phone: 819-346-1110 phoneExt: 13895 email: david.fortin@usherbrooke.ca name: Marie-Andrée Roy, Nurse role: CONTACT phone: 819-346-1110 phoneExt: 13895 email: marie-andree.roy.s-inf.ciussse-chus@ssss.gouv.qc.ca lat: 45.40008 lon: -71.89908 hasResults: False
<\|newrecord\|> nctId: NCT06356870 id: BUE briefTitle: Alveolar Cleft Reconstruction Using Bone Marrow Aspirate Concentrate and Allograft vs Iliac Cancellous Bone. acronym: BMAC overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-06-01 date: 2026-06-01 date: 2024-04-10 date: 2024-04-10 name: Cairo University class: OTHER briefSummary: radiographic and clinical assessment of alveolar cleft grafting using Allograft mixed with BMAC compared to the standard protocol of anterior iliac crest cancellous bone grafting conditions: Alveolar Cleft Grafting studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: parallel assignment primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: BMAC MIXED WITH ALLOGRAFT name: Cancellous bone from anterior iliac crest measure: bone density measure: Bone gain measure: Postoperative donor site morbidity sex: ALL minimumAge: 8 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Cairo university city: Cairo country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
<\|newrecord\|> nctId: NCT06356857 id: H-23070312 briefTitle: Assessing Repeatability and Intra-individual Variability in [O15]H2O-PET Myocardial Perfusion Imaging acronym: Heart-Wave overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-10 date: 2024-10 date: 2024-04-10 date: 2024-04-11 name: Peter Hovind class: OTHER briefSummary: This study wish to assess the reproducibility of baseline and hyperemic myocardial blood flow as well as myocardial blood flow reserve measurements with \[O15\]H2O-PET-MPI. conditions: Myocardial Blood Flow studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 20 type: ESTIMATED name: Myocardial perfusion imaging (MPI) using [O15]H2O-PET-CT measure: [O15]H2O-PET-MPI variability and repeatability coefficient estimated from 20 patients having [O15]H2O-PET-MPI done twice sex: ALL minimumAge: 50 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bispebjerg Hospital city: Copenhagen state: RegionH zip: 2400 country: Denmark name: Laila Seidelin, MD role: CONTACT phone: +4520353008 email: laila.seidelin.01@regionh.dk name: Martin Krakauer, MD, Phd. role: CONTACT email: martin.krakauer@regionh.dk name: Laila Seidelin, MD role: SUB_INVESTIGATOR name: Martin Krakauer, MD, P.hd role: SUB_INVESTIGATOR lat: 55.67594 lon: 12.56553 hasResults: False
<\|newrecord\|> nctId: NCT06356844 id: 27.02.2023-E.142568 briefTitle: The Effect of Resolvins on the Resolve of Inflammatory Low Back Pain overallStatus: RECRUITING date: 2024-02-27 date: 2024-04 date: 2024-12 date: 2024-04-10 date: 2024-04-10 name: Bezmialem Vakif University class: OTHER briefSummary: Brief Summary: Inflammatory back pain is a chronic condition localized in the axial spine and sacroiliac joints.1 It often accompanies mechanical issues like lumbar disc herniation. While non-surgical interventions such as medication, physiotherapy, and epidural steroid injections are typically the initial approach, surgical options may be considered if these prove ineffective.2 Resolvins, derived from omega-3 fatty acids, have shown promise in reducing inflammation and pain. They help to resolve inflammatory responses, promote tissue repair, and decrease disc size, potentially reducing the need for surgery.3,4 This clinical trial aims to evaluate the efficacy of adding oral resolvins to transforaminal epidural steroid injections for treating lumbar disc herniation (LDH) The control group (Group C: n=25) will receive epidural steroids, while the study group (Group R: n=25) will receive both oral omega-3 supplementation and epidural steroids on the same day. Additionally, the study group will continue taking oral omega-3 supplements for six months.
The primary outcome measure will be changes in protruded/extruded disc size assessed via MRI, with secondary outcomes including pain levels measured by the Numeric Rating Scale (NRS) and serum cytokine levels (IL-6, IL-17, IL-1 beta, TNF-alpha) over the study period.
Discussion: This trial anticipates that combining the anti-inflammatory properties of resolvins with epidural steroid injection will provide a beneficial treatment for patients suffering from inflammatory low back pain. conditions: Low Back Pain conditions: Inflammatory Response conditions: Lumbar Disc Herniation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: Resolvin supplement measure: changes in protruded/extruded disc size measure: Pain intensity score measure: Cytokine markers sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Aylin Ceren Şanlı status: RECRUITING city: Istanbul country: Turkey name: Aylin C Sanli, Asist Dr role: CONTACT phone: +0905496522412 email: aylincerensanli@hotmail.com lat: 41.01384 lon: 28.94966 facility: Aylin Ceren status: COMPLETED city: Istanbul country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
<\|newrecord\|> nctId: NCT06356831 id: Endomecryo briefTitle: National Registry of Surgical Treatment and Percutaneous Cryoablation of Parietal Endometriosis acronym: Endomercyo overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-07-31 date: 2028-01-31 date: 2024-04-10 date: 2024-04-10 name: Centre Hospitalier Intercommunal Creteil class: OTHER briefSummary: National multicentric registry of a cohort of patient with suffering parietal endometriosis, carried out by a multidisciplinary radiosurgery team conditions: Endometriosis conditions: Cryotherapy Effect conditions: Surgical conditions: Radiology studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 300 type: ESTIMATED measure: creation of a national registry for the removal of nodules by cryoablation or surgery for parietal endometriosis measure: Characterize the epidemiology of parietal endometriosis nodules measure: Characterize the epidemiology of parietal endometriosis nodules measure: To assess the impact of hormone treatment on parietal endometriosis measure: Assess the demographic distribution of parietal endometriosis measure: Evaluate pre- and post-treatment imaging characteristics of parietal endometriosis measure: Evaluate the aesthetic impact of the treatments measure: Assess the complication rate between the two groups measure: Assess the Severity of Complications according to Society (SIR) of Interventional Radiology or Cardiovascular and Interventional Radiological Society of Europe ( CIRSE) for Radiologists measure: Assess the Severity of Complications according to Clavien Dindo for the surgeon measure: Assess the recidivism rate at 3 years measure: Assess the quality of life between the two groups with PGIC-7 questionnaire measure: Assess the quality of life between the two groups with asses EHP-5 questionnaire measure: Assess the quality of life between the two groups with asses EVA questionnaire measure: Evaluate signal and morphology changes on imaging MRI of parietal endometriosis nodules after cryoablation treatment measure: Evaluate signal and morphology changes on ultrasound imaging of parietal endometriosis nodules after cryoablation treatment sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Clinique Tivoli city: Bordeaux country: France name: Horace ROMAN role: CONTACT email: Horace.roman@gmail.com lat: 44.84044 lon: -0.5805 facility: CHU bordeaux city: Bordeau country: France lat: 48.32158 lon: 3.20107 facility: CHU Clermont Ferrand city: Clermont-Ferrand country: France name: Benoit Chauveau role: CONTACT email: b_chauveau@chu-clermontferrand.fr name: Michel CANIS role: CONTACT email: mcanis@chu-clermontferrand.fr lat: 45.77966 lon: 3.08628 facility: CHI Creteil city: Créteil country: France name: Leo RAZAKAMANANTSOA role: CONTACT email: eo.razakamanantsoa@chicreteil.fr name: Yann SALHI role: CONTACT email: yann.salhi@chicreteil.fr lat: 48.78333 lon: 2.46667 facility: CHU de Lyon city: Lyon country: France name: Ana GJORGJIEVSKA-DELOV role: CONTACT email: ana.gjorgjievska-delov@chu-lyon.fr name: Gautier CHENE role: CONTACT email: Gautier.chene@chu-lyon.fr lat: 45.74848 lon: 4.84669 facility: APHP Marseille city: Marseill country: France lat: 43.29551 lon: 5.38958 facility: CHU Montpellier city: Montpellier country: France name: Cécile VERHEYDEN role: CONTACT email: c-verheyden@chu-montpellier.fr name: Claire VINCENS role: CONTACT email: c-vincens@chu-montpellier.fr lat: 43.61092 lon: 3.87723 facility: CHU Nime city: Nîmes zip: 30000 country: France lat: 43.83333 lon: 4.35 facility: AP-HP - Tenon city: Paris country: France name: Milan NAJDAW role: CONTACT email: milan.najdawi@aphp.fr name: Yohann DABI role: CONTACT email: Yohann.dabi@aphp.fr lat: 48.85341 lon: 2.3488 facility: AP-HP Hôpital Européen Georges Pompidou city: Paris country: France name: Tom BOEKEN role: CONTACT email: tom.boeken@aphp.fr name: Henri AZAIS role: CONTACT email: henri.azais@aphp.fr lat: 48.85341 lon: 2.3488 facility: APHP Cochin-Port Royal city: Paris country: France name: Maxime BARAT role: CONTACT email: maxime.barat@aphp.fr lat: 48.85341 lon: 2.3488 facility: CHU Strasbourg city: Strasbourg country: France name: Afshin GANGI role: CONTACT email: Afshin.gangi@chru-strasbourg.fr name: Emilie FALLER role: CONTACT email: Emilie.faller@chru-strasbourg.fr lat: 48.58392 lon: 7.74553 facility: CHU Toulouse city: Toulouse country: France name: Marie FARUCH role: CONTACT email: Faruch.m@chu-toulouse.fr name: Elodie CHANTALAT role: CONTACT email: Chantalat.e@chu-toulouse.fr lat: 43.60426 lon: 1.44367 facility: CH Valencienne city: Valenciennes country: France name: Thibault POCLET role: CONTACT email: Poclet-t@ch-valenciennes.fr name: Vassili FAGUE role: CONTACT email: fague-v@ch-valenciennes.fr lat: 50.35 lon: 3.53333 hasResults: False
<\|newrecord\|> nctId: NCT06356818 id: E-74555795-050.04-941155 briefTitle: Comparison of Virtual Reality and Motor Imagery Applications in Patients With Ankle Instability overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-07 date: 2024-09 date: 2024-04-10 date: 2024-04-10 name: Istanbul University - Cerrahpasa (IUC) class: OTHER briefSummary: In this study, the effects of different treatment methods for ankle instability patients are being compared aiming to find the optimal treatment. Via comparing virtual reality, motor imagery, and classic rehabilitation programs to clarify their effects on ankle static and dynamic balance, proprioception, range of motion, muscle strength, pain, function and patient satisfaction. conditions: Ankle Sprains studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: three groups with a conventional therapy control group. primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 30 type: ESTIMATED name: Conventional physiotherapy program name: Virtual reality (VR) name: Motor imagery (MI) measure: Visual Analog Scale (VAS) measure: Pressure Pain Threshold (PPT) measure: Star Excursion Balance Test (SEBT) measure: Single Leg Balance Test (SLBT) measure: Joint position sense (JPS) measure: Range of Motion (ROM) measure: Muscle strength measure: Cumberland ankle instability questionnaire (CAIT) measure: Patient satisfaction sex: ALL minimumAge: 18 Years maximumAge: 39 Years stdAges: ADULT facility: Istanbul University-Cerrahpasa (IUC) city: Istanbul country: Turkey name: Doaa HAKAM, PT role: CONTACT phone: +905345456224 email: d.hakam@ogr.iuc.edu.tr name: YILDIZ AKBABA, Assoc. Prof. role: CONTACT email: yildizanalay@iuc.edu.tr lat: 41.01384 lon: 28.94966 hasResults: False
<\|newrecord\|> nctId: NCT06356805 id: rTMS in Fibromyalgia briefTitle: rTMS Effect on Cognitive and Psychiatric Dysfunction in Patients With Fibromyalgia acronym: rTMS overallStatus: COMPLETED date: 2023-01-10 date: 2024-01-30 date: 2024-02-20 date: 2024-04-10 date: 2024-04-10 name: Assiut University class: OTHER name: Tanta University briefSummary: the aim of this work was to evaluate the effect of low frequency rTMS over the right dorsolateral prefrontal area (DLPFC) on Fibromyalgia patients. Fibromyalgia Impact Questionnaire (FIQ), Hamilton depression and Anxiety scale and different cognitive rating scales were evaluated pre-1 month post sessions and pre -post 3 months later. all eligible patients with fibromyalgia (FM) were randomized to have 20 sessions of active or sham rTMS over right DLPFC. The improvement changes in groups were compared in each rating scale. conditions: Treatment Resistant Disorders studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 42 type: ACTUAL name: repetitive transcranial magnetic stimulation measure: 1- Assessment of Fibromyalgia Impact Questionnaire (FIQ) measure: 1-Assessment of Hamilton depression (HDRS) and Hamilton Anxiety scales (HARS) (pre- post sessions and pre post three months) measure: Assessment of different cognitive rating scales (Montreal cognitive Assessment scale (MoCa), and Rey Auditory Verbal Learning Test [RAVLT], sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Eman Khedr city: Assiut zip: 11517 country: Egypt lat: 27.18096 lon: 31.18368 hasResults: False
<\|newrecord\|> nctId: NCT06356792 id: Obstetrics outcome in Abortion briefTitle: Obstetrics , Prenatal Outcomes in Recurrent Miscarriage acronym: OBPORPL overallStatus: RECRUITING date: 2024-04-21 date: 2025-03-21 date: 2025-03-21 date: 2024-04-10 date: 2024-04-10 name: Assiut University class: OTHER briefSummary: The effect of recurrent miscarriage on the outcome of the current pregnancy and if there's a relation between it and adverse out come conditions: Recurrent Miscarriage studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 102 type: ESTIMATED measure: If there's relation between recurrent abortion and having a medical disorder during current pregnancy sex: FEMALE minimumAge: 17 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Assiut University status: RECRUITING city: Assiut country: Egypt lat: 27.18096 lon: 31.18368 hasResults: False
<\|newrecord\|> nctId: NCT06356779 id: H-23066725 briefTitle: Longitudinal Study of Local Ablative Therapy in Oligometastatic Disease acronym: OLIGO-DK overallStatus: RECRUITING date: 2024-04-15 date: 2030-12-31 date: 2035-12-31 date: 2024-04-10 date: 2024-04-16 name: Gitte Fredberg Persson MD PhD class: OTHER briefSummary: This prospective national multicenter observational and interventional study aims to assess the longitudinal disease trajectory of patients with oligometastatic disease (OMD) who receive local metastasis-directed therapy. Patients with any category of OMD from any non-hematological cancer are eligible for inclusion. Local ablative therapy (LAT) includes surgical metastasectomy, radiotherapy, thermal ablation, and electroporations.
The primary objective is to assess the time to failure of LAT strategy in patients with OMD from any primary cancer treated with all LAT modalities. conditions: Oligometastatic Disease conditions: Metastases conditions: Ablation Techniques conditions: Radiotherapy conditions: Stereotactic Radiation conditions: Surgery studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 1200 type: ESTIMATED name: Local ablative therapy (LAT) measure: Time to failure of local ablative therapy (LAT) strategy measure: Progression-free survival measure: Time to widespread progression measure: Freedom from systemic treatment measure: Overall survival measure: Time to progression measure: Time to local progression measure: Local lesion control rate at 1- and 3-years post-local ablative therapy measure: Time to distant progression measure: Investigator reported grade 3-5 CTCAE (v.5.0) LAT related toxicity measure: Harms sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Copenhagen University Hospital Rigshospitalet status: NOT_YET_RECRUITING city: Copenhagen state: Capital Region Of Denmark zip: 2100 country: Denmark name: Mette Pøhl, MD PhD role: CONTACT name: Mette Pøhl, MD PhD role: PRINCIPAL_INVESTIGATOR name: Maja Maraldo, MD PhD role: SUB_INVESTIGATOR name: Morten Suppli, MD PhD role: SUB_INVESTIGATOR name: Rene H Petersen, MD PhD role: SUB_INVESTIGATOR name: Hans-Christian Pommergaard, MD PhD role: SUB_INVESTIGATOR name: Søren Møller, MD PhD role: SUB_INVESTIGATOR name: Michael Achiam, MD PhD role: SUB_INVESTIGATOR name: Mikkel Rosendahl, MD PhD role: SUB_INVESTIGATOR lat: 55.67594 lon: 12.56553 facility: Copenhagen University Hospital Herlev and Gentofte status: RECRUITING city: Herlev state: Capital Region Of Denmark zip: 2730 country: Denmark name: Michael RT Laursen, MD role: CONTACT phone: +453868 9202 email: michael.ruben.teindl.laursen@regionh.dk name: Mette Felter, MD PhD role: SUB_INVESTIGATOR name: Henriette Lindberg, MD PhD role: PRINCIPAL_INVESTIGATOR name: Eva Serup-Hansen, MD PhD role: SUB_INVESTIGATOR name: Sebastian Krog, MD role: SUB_INVESTIGATOR name: Jesper Palshof, MD PhD role: SUB_INVESTIGATOR name: Bodil Engelmann, MD PhD role: SUB_INVESTIGATOR name: Eva Ellebæk, MD PhD role: SUB_INVESTIGATOR name: Lisbet Hölmich, MD PhD role: SUB_INVESTIGATOR lat: 55.72366 lon: 12.43998 facility: Hillerød Hospital status: NOT_YET_RECRUITING city: Hillerød state: Capital Region Of Denmark zip: 3400 country: Denmark name: Maria Lendorf role: CONTACT name: Maria Lendorf, MD PD role: PRINCIPAL_INVESTIGATOR lat: 55.92791 lon: 12.30081 facility: Aarhus University Hospital status: NOT_YET_RECRUITING city: Aarhus state: Central Denmark Region zip: 8200 country: Denmark name: Mette Marie Fode, MD PhD role: CONTACT email: mettfode@rm.dk name: Mette Marie Fode, MD PhD role: PRINCIPAL_INVESTIGATOR name: Azza Khalil, MD PhD role: SUB_INVESTIGATOR name: Thomas Decker Christensen, MD PhD role: SUB_INVESTIGATOR name: Ole Graumann, MD PhD role: SUB_INVESTIGATOR name: Jørgen Bjerggaard Jensen, MD PhD role: SUB_INVESTIGATOR lat: 56.15674 lon: 10.21076 facility: Gødstrup Hospital status: NOT_YET_RECRUITING city: Herning state: Central Denmark Region zip: 7400 country: Denmark name: Trine Øllegaard role: CONTACT name: Trine Øllegaard, MD PhD role: PRINCIPAL_INVESTIGATOR lat: 56.13932 lon: 8.97378 facility: Danish Center for Particle Therapy status: NOT_YET_RECRUITING city: Aarhus state: Central Region Denmark zip: 8200 country: Denmark name: Britte Weber, MD PhD role: CONTACT name: Britta Weber, MD PhD role: PRINCIPAL_INVESTIGATOR lat: 56.15674 lon: 10.21076 facility: Aalborg University Hospital status: NOT_YET_RECRUITING city: Aalborg state: Northern Region Of Denmark zip: 9000 country: Denmark name: Jimmy Søndergaard, MD PhD role: CONTACT name: Laurids Ø Poulsen, MD PhD role: CONTACT name: Jimmi Søndergaard, MD PhD role: PRINCIPAL_INVESTIGATOR name: Laurids Ø Poulsen, MD PhD role: SUB_INVESTIGATOR name: Hella Sand, MSc role: SUB_INVESTIGATOR lat: 57.048 lon: 9.9187 facility: Odense University Hospital status: NOT_YET_RECRUITING city: Odense state: Southern Denmark Region zip: 5000 country: Denmark name: Tine Schytte, MD PhD role: CONTACT name: Tine Schytte, MD PhD role: PRINCIPAL_INVESTIGATOR name: Jørgen Johansen, MD PhD role: SUB_INVESTIGATOR name: Christina Nyborg, MD PhD role: SUB_INVESTIGATOR lat: 55.39594 lon: 10.38831 facility: Sønderborg Hospital status: NOT_YET_RECRUITING city: Sønderborg state: Southern Denmark Region zip: 6400 country: Denmark lat: 54.90896 lon: 9.78924 facility: Vejle Hospital status: NOT_YET_RECRUITING city: Vejle state: Southern Denmark Region zip: 7100 country: Denmark name: Charlotte Kristiansen, MD role: CONTACT name: Charlotte Kristiansen, MD role: PRINCIPAL_INVESTIGATOR name: Lars Fokdal, MD PhD role: SUB_INVESTIGATOR name: Lise Bentzen, MD PhD role: SUB_INVESTIGATOR lat: 55.70927 lon: 9.5357 facility: Zealand University Hospital, Roskilde and Næstved status: NOT_YET_RECRUITING city: Roskilde state: Zealand Region zip: 4000 country: Denmark name: Julie Gehl, MD DMSc role: CONTACT name: Julie Gehl, MD DMSc role: PRINCIPAL_INVESTIGATOR lat: 55.64152 lon: 12.08035 hasResults: False
<\|newrecord\|> nctId: NCT06356766 id: 30.01.2024/009 briefTitle: Investigation of Effectiveness of Telerehabilitation for Zone 2 Flexor Tendon Injuries of the Hand overallStatus: NOT_YET_RECRUITING date: 2024-04-08 date: 2024-10-08 date: 2025-04-08 date: 2024-04-10 date: 2024-04-16 name: Istanbul University class: OTHER briefSummary: The treatment process following Zone 2 flexor tendon injuries, which are particularly controversial for hand surgery, is challenging. There are various rehabilitation methods for Zone 2 flexor tendon injuries, one of which is the Modified Duran Protocol. Disruptions in the physiotherapy process lead to joint contractures, tendon adhesions, and limitations in daily life activities for patients. Due to global issues such as socioeconomic factors, physical barriers, distance, and pandemics, patients who cannot actively participate in physiotherapy miss out on the rehabilitation process.
The aim of the present study is to investigate the effectiveness of the Modified Duran protocol applied through telerehabilitation following Zone 2 flexor tendon repair. Between April and October 2024, a total of 42 adults aged 18-55 who underwent Zone 2 flexor tendon repair at Istanbul University Istanbul Faculty of Medicine will be recruited, with 21 participants in face-to-face clinic group and 21 in telerehabilitation group. Rehabilitation process will be followed for 12 weeks. The telerehabilitation group will receive exercise training on the third day. After the first training session, patients will be discharged and called to the clinic once a week for dressing changes, monitoring, exercises and if necessary, revision of the protective splint. Patients will be contacted three times a week to implement the planned program using telerehabilitation.
The face-to-face rehabilitation group will receive face-to-face clinic rehabilitation three times a week under the supervision of a physiotherapist for the first 12 weeks.
Patients will be evaluated at the end of the 5th, 6th, and 12th weeks. Data collection tools will include a 'Sociodemographic Form', 'Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire', 'Visual Analog Scale (VAS)', 'Jamar Hand Dynamometer', and 'Goniometer (Joint Range of Motion)'.
SPSS (Statistical Package for the Social Sciences) Statistics will be used for the statistical analysis of all data, with a significance level of p \<0.05 considered significant in all assessments, and accepted as two-tailed. conditions: Zone 2 Flexor Tendon Injuries of the Hand studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 42 type: ESTIMATED name: Telerehabilitation name: Face-to-face rehabilitation measure: Range of Motion measure: DASH measure: Pain of the affected hand measure: Muscle Strength sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
<\|newrecord\|> nctId: NCT06356753 id: RC19_0203 briefTitle: EndoxOmics : Exposome, Endometriosis and Fertility acronym: EndoxOmics overallStatus: COMPLETED date: 2019-09-01 date: 2021-03-31 date: 2021-03-31 date: 2024-04-10 date: 2024-04-10 name: Nantes University Hospital class: OTHER briefSummary: For several years, the effects of environmental pollution on human health have been a growing concern for the scientific community and public authorities. Among the many known chemical contaminants, persistent organic pollutants (POPs) are of particular concern because of their properties as endocrine disrupters, bioaccumulation and biomagnification. The associations between environmental pollutants, endometriosis and infertility remains poorly understood. The objective of this exploratory non interventional monocentric study conducted in the University Hospital of Nantes, is to identify endogenous molecular profiles associated with endometriosis and related infertility. This project implements an exploratory approach combining exposure and metabolomics approaches based on high-resolution mass spectrometry to identify exposure and metabolomics profiles associated with infertility, and biomarkers for potential prognostic application. conditions: Endometriosis conditions: Infertility, Female studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 87 type: ACTUAL measure: Identify endogenous molecular profiles of patients with infertile endometriosis measure: Characterize the internal chemical exposure profiles and metabolomic profiles in the different groups. measure: Compare the distribution of contaminant concentration levels and metabolomic profiles according to the media measured. sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Nantes University Hospital city: Nantes state: Loire-Atlantique zip: 44093 country: France lat: 47.21725 lon: -1.55336 hasResults: False
<\|newrecord\|> nctId: NCT06356740 id: 69HCL22_0878 id: 2023-508611-22-00 type: CTIS briefTitle: Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus acronym: PENCIL overallStatus: NOT_YET_RECRUITING date: 2024-09-01 date: 2028-11-01 date: 2029-06-01 date: 2024-04-10 date: 2024-04-10 name: Hospices Civils de Lyon class: OTHER briefSummary: Systemic lupus (SL) is a rare chronic autoimmune disease characterized by the production of autoantibodies directed against nuclear antigens, particularly native double-stranded deoxyribonucleic acid (DNA), and excessive production of antiviral cytokines: type I interferons, particularly interferon alpha (IFN-α). IFN-α production results from the excessive detection of nucleic acids (DNA or Ribonucleic Acid (RNA)) by endosomal or intracytoplasmic receptors that are capable of inducing interferon production. The precise mechanisms of cytoplasmic sensor activation remain unknown; however, recent work in the field of interferonopathies suggests a role for human endogenous retroviruses (HERVs). HERVs are remnants of ancient infections caused by exogenous retroviruses integrated into the genome during evolution and represent 8% of the human genome.Several studies have suggested a role for HERVs in the development and maintenance of an excessive immune response in lupus patients and other autoimmune diseases by affecting the type I interferons (I IFN) signalling pathway.
To date, none of the approved immunosuppressive drugs for Systemic Lupus Erythematosus (SLE) have been shown to be effective in the background treatment of SL or in preventing relapse. Consequently, there is an urgent need to identify new molecules and therapeutic avenues for disease-modifying therapies.
In this study, an innovative therapeutic strategy using a combination of nucleoside reverse transcriptase inhibitors (NRTIs), abacavir/lamivudine, is proposed to treat SLE. Thus, we propose a pilot Phase II, randomized, open-label study using NRTIs in patients with SL in remission or with low clinical activity, and evaluating a biological endpoint (IFN signature), which is a direct proxy for the drug's expected effect.
The main objective is to compare the addition of Abacavir/Lamivudine (Add-on) to standard care for 6 months, on the value of the interferon (IFN) transcriptomic signature of patients with systemic lupus with low activity as defined by the Lupus Low Disease Activity State (LLDAS). conditions: Systemic Lupus Erythematosus studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Open-label randomized, controlled study with 2 parallel arms (Add-on treatment versus standard of care treatment) primaryPurpose: TREATMENT masking: NONE count: 70 type: ESTIMATED name: Blood sample name: Treatment :Abacavir 600 mg/lamivudine 300 mg name: Lupus Impact Tracker questionnaire measure: Absolute variation in interferon signature (IFN) measure: percentage of patients maintaining LLDAS criteria measure: number of relapses measure: anti-native double-stranded DNA quantification measure: anti-extractable nuclear antigens (anti-ENA) quantification measure: interferon-α production quantification measure: Number of successful patients measure: Cumulative dose of intravenous (IV) corticosteroids measure: Lupus Impact Tracker questionnaire score measure: number of missed treatment measure: number of adverse event (AE) measure: number of serious adverse event (SAE) measure: HERVs transcription quantification sex: ALL minimumAge: 12 Years maximumAge: 65 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Groupe Hospitalier Pellegrin-CHU de Bordeaux city: Bordeaux zip: 33076 country: France name: Christophe RICHEZ, MD, PhD role: CONTACT phone: 05 56 79 56 79 phoneExt: +33 email: christophe.richez@chu-bordeaux.fr name: Christophe RICHEZ, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 44.84044 lon: -0.5805 facility: Hôpital Femme-Mère-Enfant (HCL) city: Bron zip: 69677 country: France name: Alexandre BELOT, MD, PhD role: CONTACT phone: 04 27 85 61 26 phoneExt: +33 email: Alexandre.belot@chu-lyon.fr name: Alexandre BELOT, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 45.73333 lon: 4.91667 facility: CHU de Clermont-Ferrand - Hôpital Gabriel Montpied city: Clermont-Ferrand zip: 63003 country: France name: Marc ANDRE, MD, PhD role: CONTACT phone: 0473751440 phoneExt: +33 email: mandre@chu-clermontferrand.fr name: Marc ANDRE, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 45.77966 lon: 3.08628 facility: CHU Nord de Grenoble - Albert Michallon city: Grenoble zip: 38043 country: France name: Laurence BOUILLET, MD, PhD role: CONTACT phone: 04 76 76 76 40 phoneExt: +33 email: lbouillet@chu-grenoble.fr name: Laurence BOUILLET, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 45.16667 lon: 5.71667 facility: Hôpital Claude Huriez city: Lille zip: 59037 country: France name: Éric HACHULLA, MD, PhD role: CONTACT phone: 03 20 44 56 50 phoneExt: +33 email: eric.hachulla@chru-lille.fr name: Éric HACHULLA, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 50.63297 lon: 3.05858 facility: Hôpital de la Croix-Rousse (HCL) city: Lyon zip: 69004 country: France name: Yvan JAMILLOUX, MD, PhD role: CONTACT phone: 0426732636 phoneExt: +33 email: yvan.jamilloux@chu-lyon.fr name: Yvan JAMILLOUX, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 45.74848 lon: 4.84669 facility: Hôpital Edouard Herriot (HCL) city: Lyon zip: 69437 country: France name: Thomas BARBA, MD role: CONTACT phone: 0472119583 phoneExt: +33 email: thomas.barba@chu-lyon.fr name: Thomas BARBA, MD role: PRINCIPAL_INVESTIGATOR lat: 45.74848 lon: 4.84669 facility: Hôpital Necker-Enfants malades city: Paris zip: 75015 country: France name: Brigitte BADER-MEUNIER, MD role: CONTACT phone: 0144494332 phoneExt: +33 email: brigitte.bader-meunier@aphp.fr name: Brigitte BADER-MEUNIER, MD role: PRINCIPAL_INVESTIGATOR lat: 48.85341 lon: 2.3488 facility: Hôpital Pitié-Salpêtrière city: Paris zip: 75651 country: France name: Zahir AMOURA, MD, PhD role: CONTACT phone: 01 42 17 80 01 phoneExt: +33 email: zahir.amoura@aphp.fr name: Zahir AMOURA, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 48.85341 lon: 2.3488 facility: Hôpital Lyon Sud (HCL) city: Pierre-Bénite zip: 69310 country: France name: Mael Richard, MD role: CONTACT phone: 0478861352 phoneExt: +33 email: mael.richard@chu-lyon.fr name: Mael Richard, MD role: PRINCIPAL_INVESTIGATOR lat: 45.7009 lon: 4.82511 facility: CHU de Saint-Etienne - Hôpital Nord city: Saint-Priest-en-Jarez zip: 42270 country: France name: Martin KILLIAN, MD, PhD role: CONTACT phone: 04 77 82 91 79 phoneExt: +33 email: martin.killian@chu-st-etienne.fr name: Martin KILLIAN, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 45.47501 lon: 4.37614 hasResults: False
<\|newrecord\|> nctId: NCT06356727 id: 121CET-MICROREV-DCM briefTitle: Microvascular Dysfunction Assessment to Predict Left Ventricular Reverse Remodeling acronym: MICROREV overallStatus: RECRUITING date: 2024-01-03 date: 2026-01-31 date: 2030-01-31 date: 2024-04-10 date: 2024-04-10 name: Azienda Ospedaliera Universitaria Integrata Verona class: OTHER name: Abbott Medical Devices briefSummary: Patients presenting with idiopathic dilated cardiomyopathy and left ventricle dysfunction (LVEF \<40%), naive of anti-remodeling cardiac medical therapy, will undergo invasive coronary microvascular assessment based on thermodilution. The primary endpoint, namely the left ventricle reverse remodeling, will be assessed after 12 months of optimal medical therapy based on transthoracic echocardiography. The primary endpoint will be evaluated by an independent central core lab. Patients enrolled in the study will be followed for a period of 5 years to monitor their clinical status. During the study period participants may undergo multimodality diagnostic tests including ECG telemetry monitoring, cardiopulmonary exercise testing, cardiovascular cardiac magnetic resonance. conditions: Heart Failure conditions: Left Ventricular Dysfunction conditions: Idiopathic Dilated Cardiomyopathy studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Prospective multicenter single-arm experimental study. The study aims to perform a functional study of the coronary microcirculation with pressure guides, in patients with new diagnoses of dilated cardiomyopathy and clinical indication for coronary angiography. Following this, a multiparametric imaging study with transthoracic echo cardiography will be performed. 12 months after the optimization of medical therapy, the patient will receive a clinical, laboratory and instrumental re-evaluation of transthoracic cardiac color Doppler. The primary endpoint is the recovery of left ventricular function on cardiac imaging. Follow up will continue up to 5 years from enrollment through telephone contacts, outpatient visits and review of clinical data. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 190 type: ESTIMATED name: Thermodilution based assessment of coronary microcirculation measure: Rate of Left ventricular reverse remodeling (LVRR) measure: Adverse clinical events measure: Rate of LVRR at cardiac magnetic resonance measure: Changes in functional capacity at cardiopulmonary exercise test measure: Prevalence of different CMD endotypes and their correlation with the severity of adverse cardiac remodeling. measure: Left ventricle adverse cardiac remodeling at cardiovascular magnetic resonance. sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Azienda Ospedaliera Universitaria di Ferrara status: NOT_YET_RECRUITING city: Ferrara country: Italy name: Gianluca Campo role: CONTACT name: Elisabetta Tonet role: CONTACT lat: 44.83804 lon: 11.62057 facility: Cardiothoracic and Vascular Department (DICATOV) IRCCS, Ospedale Policlinico San Martino status: NOT_YET_RECRUITING city: Genova country: Italy name: Italo Porto role: CONTACT lat: 44.40478 lon: 8.94438 facility: Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) dell'Ospedale San Raffaele status: NOT_YET_RECRUITING city: Milan country: Italy name: Matteo Montorfano role: CONTACT name: Marco Ancona role: CONTACT lat: 45.46427 lon: 9.18951 facility: Ospedale Galeazzi di Sant'Ambrogio IRCCS status: NOT_YET_RECRUITING city: Milan country: Italy name: Giovanni Monizzi role: CONTACT lat: 45.46427 lon: 9.18951 facility: University of Naples Federico II status: NOT_YET_RECRUITING city: Naples country: Italy name: Giovanni Esposito role: CONTACT name: Luigi Di Serafino role: CONTACT lat: 40.85216 lon: 14.26811 facility: Fondazione Policlinico Universitario A. Gemelli IRCCS status: NOT_YET_RECRUITING city: Roma country: Italy name: Cristina Aurigemma role: CONTACT name: Francesco Burzotta role: CONTACT name: Antonio M Leone role: SUB_INVESTIGATOR lat: 41.89193 lon: 12.51133 facility: Azienda Ospedaliero-Universitaria Sant'Andrea status: NOT_YET_RECRUITING city: Rome country: Italy name: Emanuele Barbato role: CONTACT lat: 41.89193 lon: 12.51133 facility: Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino status: NOT_YET_RECRUITING city: Torino country: Italy name: Fabrizio D'Ascenzo role: CONTACT lat: 45.07049 lon: 7.68682 facility: Azienda Ospedaliera Universitaria di Verona status: RECRUITING city: Verona zip: 37126 country: Italy name: Flavio Ribichini role: CONTACT phone: 0039 0458122320 email: flavio.ribichini@univr.it lat: 45.4299 lon: 10.98444 hasResults: False
<\|newrecord\|> nctId: NCT06356714 id: 13914704179 briefTitle: Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-05-01 date: 2025-08-01 date: 2024-04-10 date: 2024-04-10 name: Sun Jing class: OTHER briefSummary: Evaluate the efficacy and safety of Nocardia rubra cell wall skeleton in combination with prior second- or third-line regimens for the treatment of potentially hazardous colorectal cancer SD(Stable Disease) status in the real world. conditions: Colorectal Cancer conditions: Colorectal Neoplasms studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 22 type: ESTIMATED name: Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens measure: Progression-free survival(PFS) measure: Overall survival (OS) measure: Objective remission rate (ORR) measure: Disease Control Rate (DCR) measure: Incidence and extent of major security incidents measure: Quality of Life Score (QoL) for tumor patients sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06356701 id: dongyandl briefTitle: Tumor Nutritional Therapy in the First-line Treatment of Stage IV NSCLC overallStatus: RECRUITING date: 2024-04-15 date: 2024-12-31 date: 2025-12-31 date: 2024-04-10 date: 2024-04-10 name: The First Affiliated Hospital of Dalian Medical University class: OTHER briefSummary: A Single-center, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Tumor Nutritional Therapy Combined With Immune Checkpoint Inhibitors and Chemotherapy in the First-line Treatment of Stage IV NSCLC Without Driver Gene Mutations conditions: Long-Term Effects Secondary to Cancer Therapy studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 120 type: ESTIMATED name: Cancer nutritional treatment regimen (Spirulina Bifidobacterium Capsules, Fish Oil Grape Seed Blueberry Soft Capsules, Ganoderma Spore Oil Soft Capsules) measure: PFS measure: Assessment of global disorders in patients with cancer measure: ORR sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: DongYan status: RECRUITING city: Dalian City state: Liaoning zip: 116000 country: China name: DongYan Dong role: CONTACT phone: 18098876750 email: dongyan979828@hotmail.com hasResults: False
<\|newrecord\|> nctId: NCT06356688 id: 13914704178 briefTitle: A Clinical Study on the Efficacy and Safety of Paclitaxel Polymer Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2025-04-20 date: 2025-06-20 date: 2024-04-10 date: 2024-04-10 name: Sun Jing class: OTHER briefSummary: The purpose of this study is to investigate the efficacy and safety of neoadjuvant treatment of locally advanced esophageal squamous carcinoma with a PD-1/CTLA-4 bispecific antibody (cadonilimab) in combination with platinum-containing chemotherapy (paclitaxel polymer micelles combined with cisplatin). Includes pathologic complete remission rates (pCR rates) after 2-4 cycles of cadonilimab combination chemotherapy. The objective remission rate (ORR), major pathologic remission rate (MPR), R0 resection rate and 2-year overall survival (OS) and progression-free survival (OS) rates, and safety of neoadjuvant treatment of locally advanced esophageal squamous carcinoma with cadonilimab combined with chemotherapy. conditions: Locally Advanced Esophageal Squamous Cell Carcinoma conditions: Neoadjuvant Therapy studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: paclitaxel polymer micelles and cisplatin combined with Camrelizumab primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: paclitaxel polymer micelles and cisplatin combined with Cadonilimab measure: Pathological complete response (pCR) rates measure: Objective Rate of Effectiveness (ORR) measure: R0 Removal Rate measure: 2-year overall survival rate measure: 2-year disease free survival rate measure: major pathological response (MPR) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06356675 id: A single-arm pilot briefTitle: A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2028-07-01 date: 2028-07-01 date: 2024-04-10 date: 2024-04-10 name: The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine class: OTHER briefSummary: Immune resistance after treatment, there is no standard treatment, one of the most important and the most effective measures is immune to combination therapy。Targeted angiogenesis therapy has always been the focus of research on the treatment of NSCLC patients with progressive disease after immunotherapy. From the mechanism of action, angiogenesis and immunosuppression are interrelated processes. conditions: Advanced NSCLC studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 33 type: ESTIMATED name: Tislelizumab name: Anlotinib measure: objective response rate measure: progression free survival time measure: over survival time measure: disease control rate measure: safety including any grade adverse events sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06356662 id: KY-2023-198 briefTitle: Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease overallStatus: RECRUITING date: 2024-01-23 date: 2024-08-31 date: 2024-12-31 date: 2024-04-10 date: 2024-04-10 name: The Fourth Affiliated Hospital of Zhejiang University School of Medicine class: OTHER briefSummary: To evaluate the efficacy and safety of tenofovir disoproxil fumarate in the treatment of Parkinson's disease. The changes of motor symptoms and the occurrence of adverse reactions in early Parkinson's disease patients who took tenofovir disoproxil fumarate and did not take Tenofovir disoproxil fumarate at different time points were compared. conditions: Parkinson Disease studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Tenofovir Disoproxil Fumarate measure: UPDRS III（Unified Parkinson's Disease Rating Scale part 3） measure: Non-Motor Symptom Scale（NMSS） measure: creatinine(μmoI/L) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Guohua Zhao status: RECRUITING city: Hangzhou state: Zhejiang country: China name: Zhao Guohua, Doctor role: CONTACT phone: +86 13777812308 email: gzhao@zju.edu.cn lat: 30.29365 lon: 120.16142 hasResults: False
<\|newrecord\|> nctId: NCT06356649 id: ESOGU2 briefTitle: Investigation of the Effects of Pressure Support Ventilation and Positive Airway Pressure Modes During Extubation overallStatus: COMPLETED date: 2023-03-15 date: 2024-01-15 date: 2024-01-20 date: 2024-04-10 date: 2024-04-10 name: Eskisehir Osmangazi University class: OTHER briefSummary: Controlled ventilation is applied to patients intubated for general anesthesia. Additionally, positive end-expiratory pressure (PEEP) and pressure support are mechanical ventilation modes that have been used in general anesthesia practice for many years. When the recovery-extubation phase is reached, intermittent bag-mask ventilation is usually used and the patient is allowed to breathe spontaneously and is extubated when an adequate respiratory level is reached. It has been shown in previous studies that the use of intermittent mask ventilation causes postoperative atelectasis. Different methods have been used to prevent postoperative atelectasis. In our study, we aimed to observe the effect of terminating general anesthesia at the end of the operation and using PEEP and pressure-supported ventilation during the extubation phase on early complications. conditions: Anesthesia studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 199 type: ACTUAL name: extubation measure: Complications developing during recovery-extubation measure: hemodynamic changes measure: hemodynamic data sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Eskisehir Osmangazi University Medical Faculty city: Eskisehir state: Odunpazarı zip: 26040 country: Turkey lat: 39.77667 lon: 30.52056 hasResults: False
<\|newrecord\|> nctId: NCT06356636 id: P1216/2022 briefTitle: Impact of the Financial Inclusion Improves Sanitation and Health acronym: FINISH overallStatus: RECRUITING date: 2022-01-01 date: 2025-12-31 date: 2025-12-31 date: 2024-04-10 date: 2024-04-10 name: Amref Health Africa class: OTHER briefSummary: The goal of this interventional study is to evaluate the impacts of Financial Inclusion improvement sanitation and Health (FINISH) interventions in Kenya's Homa Bay County and Uganda's Kamwenge District among children under five. The main questions it aims to answer are:
1. What is the estimated impact of the FINISH model on health outcomes (diarrhoea occurrence and hygienic behaviour) as well as social (school attendance and sanitation) in the intervention groups?
2. What are the perspectives, attitudes, and practices of various stakeholders (communities, governments, entrepreneurs, and financiers) regarding the FINISH model?
3. What is the cost-effectiveness of the FINISH model, including the amount of leverage funds generated?
The FINISH model postulates that countries will be supported to improve the enabling business environment for sanitation, markets to offer improved safely managed services and products at an affordable price, and formal and informal financial institutions will offer more funding to businesses and households for satiation and hygiene.
Researchers will then compare intervention areas (Homa Bay in Kenya and Kamwenge in Uganda) with control areas (Siaya and Bushenyi in Kenya and Uganda, respectively) to see if the FINISH intervention leads to improved sanitation, health outcomes, and economic benefits. conditions: Health Knowledge, Attitudes, Practice studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The participants are divided into two or more groups, with each group receiving a different intervention or a control condition. The outcomes of each group are compared at the end of the study to assess the effectiveness of the intervention. primaryPurpose: HEALTH_SERVICES_RESEARCH masking: QUADRUPLE maskingDescription: to be updated whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 1090 type: ESTIMATED name: Financial Inclusion Improves Sanitation and Health measure: Health outcome, measured as, Proportion of households with diarrhoea occurrence in children under five years, and social outcome measured as proportion of households whose children missed school due to diarrhoea occurrence sex: ALL minimumAge: 0 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Homa Bay county status: RECRUITING city: Homa Bay country: Kenya name: Martin Dr Muchangi, PhD role: CONTACT phone: 0721453712 email: martin.muchangi@amref.org lat: -0.52731 lon: 34.45714 hasResults: False
<\|newrecord\|> nctId: NCT06356623 id: SHDC2202020401 briefTitle: A Risk Prediction Model of Postoperative Nausea and Vomiting in Patients With Liver Cancer overallStatus: NOT_YET_RECRUITING date: 2024-05-05 date: 2024-08-05 date: 2024-08-06 date: 2024-04-10 date: 2024-04-10 name: Shanghai Zhongshan Hospital class: OTHER briefSummary: PONV management has been recommended as a necessary part of enhanced recovery protocols during the perioperative period, and PONV risk assessment is, therefore, a necessary first step in determining the number of medications or strategies for prophylaxis and treatment by considering the number of modifiable and non-modifiable risk factors. However, the external validity of two commonly-used PONV prediction models for patients undergoing liver surgery is unsatisfied, and need to be updated for liver cancer populations to better inform personalized perioperative care regime and individualized decision-making in clinical practice. conditions: Nausea and Vomiting, Postoperative conditions: Liver Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 476 type: ESTIMATED name: 1 measure: Postoperative nausea and vomiting sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06356610 id: ALCS-REG-23-08-HT briefTitle: Pharmacokinetic and Subjective Effects of Heated Tobacco Products overallStatus: RECRUITING date: 2024-02-06 date: 2024-09 date: 2025-06 date: 2024-04-10 date: 2024-04-10 name: Altria Client Services LLC class: INDUSTRY name: Celerion briefSummary: This is a randomized, controlled, six-way crossover clinical study to characterize the nicotine PK (pharmacokinetic) and subjective effects of HTPs (Heated Tobacco Products) comprised of 2 menthol varieties and 2 tobacco flavor varieties (Ploom® HTPs, Japan Tobacco Inc.) in adult menthol and non-menthol combustible cigarette smokers (males and females between the ages of 22 and 65). The study will include participants' UBCC (Usual Brand Combustible Cigarette) and a nicotine gum (Nicorette®) as high and low abuse liability reference products, respectively, to the HTP. Study participation is expected to last up to 34 days, including a 28-day screening period (that includes a 5-day at-home HTP product trial period), and a 6-day in-clinic confinement period (from Check-in \[Day -1\] through the end-of-study \[EOS\] visit on Day 6). conditions: Tobacco Use studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: This is a randomized, controlled, six-way crossover clinical study to characterize the nicotine PK and subjective effects of HTPs (2 menthol varieties, Products A and B; 2 tobacco flavor varieties, Products C and D). The study will include participants' UBCC (Product F) and a nicotine gum (Product E) as high and low abuse liability reference products. Sponsor will prepare the randomization schedule. On Day -1 participants will be randomized at 1:1:1:1:1:1 ratio into 1 of 6 sequences as listed below. At least 60 participants will be randomized to ensure approximately 48 completed participants, with approximately 24 menthol and 24 non-menthol cigarette smokers. Participants will be stratified by sex and cigarette type for each of the sequences. A 6x6 Latin Square with the following sequences will be used for the randomization: Sequence 1 = ABFCED Sequence 2 = BCADFE Sequence 3 = CDBEAF Sequence 4 = DECFBA Sequence 5 = EFDACB Sequence 6 = FAEBDC. primaryPurpose: OTHER masking: SINGLE maskingDescription: Study participants will know when they are using their UBCC (usual brand combustible cigarette) and the nicotine gum. However, participants will not be informed of which Ploom® HTS (heated tobacco stick) product they are using. Participants will not see the stick or device packaging. whoMasked: PARTICIPANT count: 60 type: ESTIMATED name: Test Product A name: Test Product B name: Test Product C name: Test Product D name: Reference Product E name: Reference Product F measure: Plasma Nicotine Concentration Pharmacokinetic (PK) Measurement measure: Product Liking of Heated Tobacco Products (HTP) measure: Tobacco Nicotine Withdrawal Questionnaire measure: Direct Effects of Product Questionnaire measure: Use the Product Again Questionnaire measure: Modified Cigarette Evaluation Questionnaire (mCEQ) - Cigarette measure: Modified Cigarette Evaluation Questionnaire - HTP measure: Modified Cigarette Evaluation Questionnaire-NRT measure: Product Use for HTP-Units Dispensed measure: Product Use for UBCC-Units Dispensed measure: Product Use for Nicotine Gum-Units Dispensed measure: Product Use for HTP-Puff Count measure: Product Use for UBCC-Puff Count measure: Physiological Heart Rate (HR) Assessment-HTP measure: Physiological Heart Rate (HR) Assessment-UBCC measure: Physiological Heart Rate (HR) Assessment-Nicotine Gum sex: ALL minimumAge: 22 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Alliance for Multispecialty Research, LLC status: RECRUITING city: Lexington state: Kentucky zip: 40509 country: United States name: Mark Adams, MD role: CONTACT phone: 859-264-8999 email: Mark.adams@amrllc.com lat: 37.98869 lon: -84.47772 facility: QPS Bio-Kinetic status: RECRUITING city: Springfield state: Missouri zip: 65802 country: United States name: Donald W Burkindine, DO role: CONTACT phone: 417-893-6161 email: donald.burkindine@qps.com lat: 37.21533 lon: -93.29824 facility: Alliance for Multispecialty Research, LLC status: RECRUITING city: Knoxville state: Tennessee zip: 37920 country: United States name: William Smith, MD role: CONTACT phone: 865-305-9100 email: william.smith@amrllc.com lat: 35.96064 lon: -83.92074 hasResults: False
<\|newrecord\|> nctId: NCT06356597 id: KY2024-004-A briefTitle: Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial overallStatus: RECRUITING date: 2024-04-01 date: 2025-12-12 date: 2027-12-12 date: 2024-04-10 date: 2024-04-10 name: Jing-yuan Fang, MD, Ph. D class: OTHER briefSummary: The aim of this study is to evaluate the efficacy and safety of Tislelizumab with Fruquintinib, Metronidazole treatment in MSS/MSI-L advanced colorectal cancer patients with high abundance of Fusobacterium nucleatum in a single arm Phase II clinical. conditions: Colorectal Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 25 type: ESTIMATED name: Tislelizumab with Fruquintinib, Metronidazole measure: objective response rate sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai First People's Hospital status: RECRUITING city: Shanghai country: China name: Qi Li role: CONTACT lat: 31.22222 lon: 121.45806 facility: Shanghai Ninth People's Hospital status: NOT_YET_RECRUITING city: Shanghai country: China name: Yanjie Zhang role: CONTACT lat: 31.22222 lon: 121.45806 hasResults: False
<\|newrecord\|> nctId: NCT06356584 id: SDZLEC2024-078-01 briefTitle: Sintilimab Combined With Fruquintinib/Regorafenib ± Radiotherapy for Third-line Treatment of Advanced Metastatic Colorectal Cancer overallStatus: RECRUITING date: 2024-04-01 date: 2026-10-01 date: 2026-10-01 date: 2024-04-10 date: 2024-04-10 name: Shandong Cancer Hospital and Institute class: OTHER briefSummary: Colorectal cancer (CRC) is a significant cause of morbidity and mortality worldwide. Its early clinical manifestations are often subtle, leading to late-stage diagnosis in about 30% of cases with distant metastases. Liver metastases are widespread and associated with poor prognosis, especially in terms of response to immunotherapy. Despite advancements in first- and second-line treatments, third-line therapies for advanced CRC remain limited, emphasizing the need for novel strategies. This prospective study evaluates the efficacy of combined therapy involving Sintilimab, Fruquintinib/Regorafenib, and radiotherapy in advanced CRC. The study cohort comprises patients with non-liver metastatic advanced CRC and those with liver metastases, each receiving tailored treatment protocols. The primary objectives are to assess progression-free survival (PFS), overall survival (OS), and treatment response rates. Subgroup analyses will focus on liver metastases to delineate their impact on treatment outcomes. The rationale for this study stems from the intricate interplay between immunotherapy, targeted therapy, and radiotherapy in CRC management. Previous data suggest a negative correlation between liver metastases and immunotherapy efficacy, necessitating a comprehensive approach integrating multiple treatment modalities. Radiotherapy, particularly stereotactic body radiation therapy (SBRT), has shown promise in controlling liver tumors and modulating the tumor microenvironment, potentially enhancing immunotherapy responses. This study aims to provide valuable insights into optimizing third-line and subsequent therapies for advanced CRC by elucidating the efficacy and safety of this combined treatment approach. The findings may pave the way for personalized treatment strategies tailored to individual patient characteristics, ultimately improving clinical outcomes in this challenging disease setting. conditions: Colorectal Cancer conditions: Immunotherapy conditions: Radiotherapy conditions: Targeted Therapy studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 141 type: ESTIMATED name: Sintilimab measure: Progression-free survival (PFS) measure: Overall response rate (ORR) measure: Disease control rate (DCR) measure: Overall survival (OS) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Jinbo Yue status: RECRUITING city: Jinan state: Shandong zip: 250000 country: China name: Jin Bo Yue role: CONTACT phone: 0531-67626442 phoneExt: 0531-67626442 email: Len.Xu@hotmail.com lat: 36.66833 lon: 116.99722 hasResults: False
<\|newrecord\|> nctId: NCT06356571 id: LPS18183 id: U1111-1298-7348 type: OTHER domain: WHO ICTRP briefTitle: A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma acronym: SubQSA overallStatus: NOT_YET_RECRUITING date: 2024-06-11 date: 2027-01-08 date: 2027-07-15 date: 2024-04-10 date: 2024-04-17 name: Sanofi class: INDUSTRY briefSummary: The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lines of therapy. conditions: Plasma Cell Myeloma Refractory studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 64 type: ESTIMATED name: Isatuximab SC-OBDS name: Montelukast name: Dexamethasone name: Acetaminophen name: Diphenhydramine name: Methylprednisolone name: Carfilzomib measure: Overall response rate (ORR) measure: Number of participants with infusion reactions (IRs) measure: Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and laboratory abnormalities (per NCI-CTCAE grade or PCSA if NCI-CTCAE scale is not applicable) measure: Number of participants with injection site reactions (ISRs) measure: CR or better measure: VGPR or better measure: Duration of response (DOR) measure: Time to first response (TT1R) measure: Time to best response (TTBR) measure: Patient experience and Satisfaction Questionnaire v2 (PESQ v2) measure: Positivity titer of anti-drug antibodies (ADA) in a subset of 15 participants measure: Maximum observed concentration (Cmax) of isatuximab in a subset of 15 participants measure: Cumulative area under the curve over the first 4 weeks of isatuximab treatment (AUC4 weeks) in a subset of 15 participants sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06356558 id: IRB-300010279 id: R01CA271303 type: NIH link: https://reporter.nih.gov/quickSearch/R01CA271303 briefTitle: Adapting Enhanced Recovery Programs for Low Health Literacy Patients overallStatus: NOT_YET_RECRUITING date: 2026-05 date: 2027-08 date: 2028-05 date: 2024-04-10 date: 2024-04-10 name: University of Alabama at Birmingham class: OTHER name: National Cancer Institute (NCI) briefSummary: Low health literacy patients are a vulnerable population at high-risk for surgical disparities including longer hospital stays, more complications, and more readmissions. This study will adapt enhanced recovery programs (ERPs) to low health literacy patients with a multilevel, health literacy-based implementation strategy (called VISACT - VISuAl aids, Coach providers in communication, and Train organizations in health literacy) to improve ERP fidelity and thereby outcomes. In the final aim of this project (Specific Aim 3), the VISACT intervention will be tested in a pilot trial. Findings from this study will lay the foundation for a multi-institutional stepped-wedge trial and establish key principles for adapting interventions to eliminate disparities. conditions: Surgery conditions: Health Knowledge, Attitudes, Practice conditions: Colorectal Disorders studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This pilot study will be a pre-post trial of the intervention (VISACT - VISuAl aids, Coach providers in communication, and Train organizations in health literacy) at 2 sites. This design was selected because the intervention is an implementation strategy and it will not be possible to randomize patients to a non-intervention arm once the VISACT is delivered to a facility. All patients, providers, and organizational units will be subject to downstream effects of VISACT once implemented. primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 1050 type: ESTIMATED name: Educational intervention (VISACT) measure: Reach - the primary outcome will be to assess the reach of the intervention (VISACT) on patients and providers. measure: Efficacy - Length-of-stay of index surgical hospitalization measure: Adoption - Completion rate of the intervention (VISACT) by participants per month measure: Implementation - Fidelity rate of patients with components of the Enhanced Recovery Program measure: Maintenance - Long-term adoption rate of the intervention (VISACT) per year measure: Efficacy - Readmission rate measure: Efficacy - Complications rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06356545 id: OMICS_CODE_01 briefTitle: Phenotype and Multi-omics Analysis of Children With Congenital Diarrhea and Enteropathy in China overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-04 date: 2026-10 date: 2024-04-10 date: 2024-04-10 name: Children's Hospital of Fudan University class: OTHER briefSummary: This study will establish a clinical cohort of children with congenital diarrhea and enteropathy (CODE), mine biomarkers of CODE through multi-omics technology and construct a clinical risk prediction model. conditions: Diarrhea Infantile studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 60 type: ESTIMATED measure: Clinical phenotype of congenital diarrhea and enteropathy in China measure: Biomarkers of congenital diarrhea and enteropathy with diagnostic value through microbiome, metabolome and proteome features measure: Cinical risk prediction model for congenital diarrhea and enteropathy built by artificial intelligence and machine learning sex: ALL minimumAge: 1 Month maximumAge: 3 Years stdAges: CHILD hasResults: False
<\|newrecord\|> nctId: NCT06356532 id: 202312197544 briefTitle: the Intensive Care Unit Diary for Liver Transplant Recipients overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-12-31 date: 2025-12-31 date: 2024-04-10 date: 2024-04-10 name: Chang Gung Memorial Hospital class: OTHER briefSummary: the purpose of this study is to assess the effectiveness of the intensive care unit diary for intensive care unit liver transplant recipients. conditions: Liver Transplant Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The participants in the control group received the routine care including communication and companionship provided by the nurses of the intensive care unit.
The participants in the intervention group received the intensive care unit diary writing and reading. Participants are required to write at least one sentence daily. The primary writers will be the patients themselves, and in cases where patients are unable to write, their family members will write on their behalf. After completion, the diary will be handed over to the patients to review its contents for at least 10 minutes before bedtime, allowing them to write down their immediate reflections and thoughts on when they read. This process will continue until the 14th day post-operation. primaryPurpose: PREVENTION masking: SINGLE maskingDescription: Outcomes Assessor is blinded to the group assignments of the patients. She is tasked with collecting the measured outcomes from the patients. Data collection will be conducted by co-principal investigator of the research team. She will distribute the questionnaires at enrollment, and on the 7th and 14th days post-operation. Once notified by the researchers, data collector will distribute and collect the questionnaires. Upon completion, the questionnaires will be sealed in envelopes by the data collectors. whoMasked: OUTCOMES_ASSESSOR count: 56 type: ESTIMATED name: intensive care unit diary measure: change from baseline in depression on the Depression-Anxiety-Stress scale at post operation day 7 and day 14 measure: change from baseline in anxiety on the Depression-Anxiety-Stress scale at post operation day 7 and day 14 measure: change from baseline in stress on the Depression-Anxiety-Stress scale at post operation day 7 and day 14 measure: change from baseline in sense of coherence on the Sense of Coherence Scale at post operation day 7 and day 14 measure: change from baseline in emotional stress on the Brief Symptom Rating Scale at post operation day 7 and day 14 measure: change from baseline in delirium on the intensive care delirium screening checklist at post operation day 1 and day 14 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06356519 id: YOUNGBC-29 briefTitle: Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer overallStatus: RECRUITING date: 2024-03-01 date: 2025-03-01 date: 2025-04-01 date: 2024-04-10 date: 2024-04-10 name: Fudan University class: OTHER briefSummary: The aim of this trial is to explore the real-world effectiveness and poteintial predictors of Sacituzumab Govitecan in Chinese metastatic breast cancer patients. conditions: Breast Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 150 type: ESTIMATED name: Sacituzumab Govitecan measure: PFS measure: ORR measure: OS measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 sex: FEMALE minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fudan University Shanghai Cancer Center status: RECRUITING city: Shanghai state: Shanghai zip: 200032 country: China name: Biyun Wang role: CONTACT phone: 18017312387 email: pro_wangbiyun@163.com lat: 31.22222 lon: 121.45806 hasResults: False
<\|newrecord\|> nctId: NCT06356506 id: 2022-P2-338-01 briefTitle: A Study on Factors of Biochemical Response in Autoimmune Hepatitis overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2034-05-01 date: 2034-05-01 date: 2024-04-10 date: 2024-04-19 name: Beijing Friendship Hospital class: OTHER briefSummary: The goal of this observational study is to clarify the clinical characteristics of autoimmune hepatitis (AIH) in China. The main questions it aims to answer are:
Human leukocyte antigen (HLA) gene susceptibility in Chinese AIH patients prognostic factors associated with AIH Participants will provide liver tests results and details of treatment during follow-up. conditions: Autoimmune Hepatitis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 630 type: ESTIMATED measure: Alanine aminotransferase (ALT) recovery measure: Aspartate transaminase (AST) recovery measure: Immunoglobulin G (IgG) recovery measure: Death measure: Liver transplantaiton measure: Progression to hepatocellular carcinoma (HCC) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Friendship Hospital, Capital Medical University city: Beijing zip: 100050 country: China lat: 39.9075 lon: 116.39723 hasResults: False
<\|newrecord\|> nctId: NCT06356493 id: OBIIA CMNT briefTitle: Prophylactic Occlusion Balloons of Both Internal Iliac Arteries in Caesarean Hysterectomy for PASD overallStatus: COMPLETED date: 2020-01-02 date: 2022-12-31 date: 2022-12-31 date: 2024-04-10 date: 2024-04-10 name: Tunis University class: OTHER briefSummary: The placenta accreta spectrum is a heterogeneous disorder due to abnormal placental invasion into the uterine wall putting at risk the lives of the patients by causing a massive hemorrhage. Its incidence is increasing due to the rise of the cesarean section. The management of this spectrum is multidisciplinary but not yet codified. Hysterectomy-caesarean, though hemostatic surgery, remains the standard Gold. Several adjuvant treatments have emerged in recent years to minimize the risk of bleeding and morbidity of these disorders including the internal-iliac prophylactic occlusion balloons.
The aim of the study is to demonstrate the effect of prophylactic occlusion balloons in both uterine iliac arteries in the management of placental accreta spectrum disorders. conditions: Hemorrhage conditions: Placenta Accreta Spectrum conditions: Cesarean Section Complications studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 38 type: ACTUAL name: caesarean hysterectomy with prior placement of prophylactic occlusion balloons of both internal iliac arteries name: caesarean hysterectomy without prior placement of prophylactic occlusion balloons of both internal iliac arteries measure: calculated blood loss measure: Transfusion peroperatively measure: Duration of surgery measure: Postoperative hospital stay measure: Postoperative transfer to the intensive care unit measure: Morbidity sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Haithem Aloui city: Manouba state: Nabeul zip: 2010 country: Tunisia lat: 36.80803 lon: 10.09721 facility: Haithem Aloui city: Tunis state: Nabeul zip: 2010 country: Tunisia lat: 36.81897 lon: 10.16579 hasResults: False
<\|newrecord\|> nctId: NCT06356480 id: 266 briefTitle: 1% Acetic Acid vs Normal Saline Dressing inManagement of Diabetic Foot overallStatus: ACTIVE_NOT_RECRUITING date: 2023-10-01 date: 2024-04 date: 2024-04 date: 2024-04-10 date: 2024-04-10 name: Dr. Muhammad Naeem class: OTHER briefSummary: Chronic diabetic wounds are those wounds that are persistent and do not respond to any sort of treatment. The concept of using topical antiseptics on open wounds is to prevent and treat infections. They also help to shorten the time taken to heal the wounds. The use of topical agents on wounds to prevent infection is a minimal ability to develop resistance to the microorganisms. Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen with innate resistance to many antibiotics. In places that are economically backward, these problems get compounded by the inability of patients to afford newer expensive drugs. Topically applied dilute acetic acid, which is cheap and easily available, has been found to be effective in such chronic diabetic wounds conditions: Granulation of Chronic Diabetic Wounds conditions: Diabetic Wounds studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 74 type: ACTUAL name: 1% Acetic acid dressing measure: Early epithelialization and granulation sex: ALL minimumAge: 40 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Pak Emirates military hospital city: Rawalpindi state: Punjab country: Pakistan lat: 33.6007 lon: 73.0679 hasResults: False
<\|newrecord\|> nctId: NCT06356467 id: FARINET briefTitle: Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENs acronym: FARINET overallStatus: ACTIVE_NOT_RECRUITING date: 2023-11-21 date: 2024-12-31 date: 2024-12-31 date: 2024-04-10 date: 2024-04-12 name: IRCCS San Raffaele class: OTHER briefSummary: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) represent the most common NeuroEndocrin Neoplasms (NEN) site, comprising 55-70% of all NENs, and they are extremely heterogeneous diseases in terms of clinical presentation and aggressiveness. In recent years there has been a significant increase in the incidence of such neoplasms, partially due to incidental findings of small indolent lesions. However, the behavior of GEP- NEN is variable and mainly dictated by some factors as age, sex, histologic grade, primary site, and stage at diagnosis1. As for grade which is defined by the proliferative activity as measured by mitotic count or ki67 staining, some 75% of neoplasms fall into the G1 grading category, 15% into the G2 category, and 10% into the G3 category. The probability of developing metastases is directly correlated with grading. In addition, the grading of GEP-NENs is also correlated with the type of differentiation of the neoplasm (well differentiated or poorly differentiated). Managing the complexity of this type of neoplasm has made it necessary to stratify patients into progression risk classes. The therapeutic approach is accordingly defined, and may include different treatments (surgery, loco-regional, targeted therapies, chemotherapies,...). Among treatments, the most widely used for patients with well-differentiated NENs are somatostatin analogs (SSAs), targeted therapies, and the combination of oral capecitabine and temozolomide. Systemic intravenous chemotherapy is instead employed in a subset of G3 neoplasms, especially if poorly differentiated. conditions: Neuroendocrine Tumors conditions: GEP-NET studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 450 type: ESTIMATED measure: Global Progression Free Survival (PFS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS OSpedale San Raffaele city: Milan zip: 20132 country: Italy lat: 45.46427 lon: 9.18951 hasResults: False
<\|newrecord\|> nctId: NCT06356454 id: KAPCON-CR briefTitle: Knowledge, Attitudes and Practices of Paediatric Cardiologists About Cardiac Rehabilitation in Children With Congenital Heart Disease overallStatus: NOT_YET_RECRUITING date: 2024-06-02 date: 2025-06-02 date: 2025-12-02 date: 2024-04-10 date: 2024-04-15 name: Karamanoğlu Mehmetbey University class: OTHER briefSummary: Despite significant clinical benefits and recommendations of clinical practice guidelines to refer patients for exercise and physical activity counselling in the capacity of cardiac rehabilitation (CR), CR is largely underutilised and not implemented effectively. Studies have reported that the reasons for the low implementation of CR are multifactorial at the healthcare system, physician and patient levels. Therefore, the aim of this study was to investigate the knowledge, attitudes and practical applications of paediatric cardiologists regarding cardiac rehabilitation and specifically exercise and physical activity in children with congenital heart disease (CHD). conditions: Physician's Role studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Questionnaire on knowledge, attitudes and practices of paediatric cardiologists about cardiac rehabilitation in children with congenital heart disease measure: The score of Questionnaire on knowledge, attitudes and practices of paediatric cardiologists about cardiac rehabilitation in children with congenital heart disease sex: ALL minimumAge: 32 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06356441 id: B2024-039-01 briefTitle: Artificial Intelligence-supported Reading Versus Standard Double Reading for the Interpretation of Magnetic Resonance Imaging in the Detection of Local Recurrence for Nasopharyngeal Carcinoma: a Randomised Controlled Multicenter Study overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-04 date: 2026-04 date: 2024-04-10 date: 2024-04-10 name: Sun Yat-sen University class: OTHER briefSummary: The aim of this randomized controlled study is to investigate whether the previously developed artificial intelligence model can triage post-radiotherapy magnetic resonance images of patients with nasopharyngeal carcinoma and assist radiologists in their interpretation. conditions: Artificial Intelligence Supported Image Reviewing studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 10400 type: ESTIMATED name: AI measure: sensitivity measure: specificity measure: positive predictive value measure: negative predictive value measure: total time of interpretation for all the MR images measure: the rate of discussion with a third radiologist measure: the detection rate of local recurrence in the AI-supported reading group measure: the sensitivity in the subgroups of different rT-stage measure: the incidence of cases whose recurrent risks and contours cannot be provided by the AI model sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Sun Yat-Sen University Cancer Center city: Guangzhou state: Guangdong zip: 510060 country: China name: Fang-Yun Xie role: CONTACT phone: +8602087342926 email: xiefy@sysucc.org.cn name: Pu-Yun OuYang role: CONTACT phone: +8602087342926 email: ouyangpy@sysucc.org.cn name: Fang-Yun Xie role: PRINCIPAL_INVESTIGATOR lat: 23.11667 lon: 113.25 hasResults: False
<\|newrecord\|> nctId: NCT06356428 id: KARYÖN-DR briefTitle: Psychometric Properties and Cross-cultural Adaptation of the Turkish Version of Physcian Attitudes Toward Cardiac Rehabilitation and Referral Scale-Revised (PACRR-R) overallStatus: NOT_YET_RECRUITING date: 2024-05-13 date: 2025-05-13 date: 2025-08-13 date: 2024-04-10 date: 2024-04-15 name: Karamanoğlu Mehmetbey University class: OTHER briefSummary: Research has reported that the reasons for low implementation of CR are multifactorial at the health system, physician and patient levels. It has also been found that patients are more likely to initiate CR if physicians strongly and positively promote the importance of CR participation. Unfortunately, there are insufficient and ineffective data on CR, referral to CR and both clinical and cost-effectiveness outcomes of CR in Turkey. In this context, it is important to examine more objectively from the perspective of physicians who play a key role in referring patients to CR. However, in our country, there is no relatively objective measurement tool to evaluate physicians' attitudes towards CR. Therefore, this study aims to adapt the original "Physician Attitudes towards Cardiac Rehabilitation and Referral Scale-Revised (PACRR-R)" into Turkish and to examine its psychometric properties. conditions: Physician's Role studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Physcian Attitudes toward Cardiac Rehabilitation and Referral Scale-Revised (PACRR-R) measure: Physician Attitudes toward Cardiac Rehabilitation and Referral (PACRR)-Revised Scale Score sex: ALL minimumAge: 25 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06356415 id: Dex Dex in infraclavicular briefTitle: Infraclavicular Brachial Plexus Block With Bupivacaine Alone or With Both Dexmedetomidine and Dexamethasone overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-08-30 date: 2024-09-30 date: 2024-04-10 date: 2024-04-10 name: Suez Canal University class: OTHER briefSummary: Upper-extremity regional anesthetic techniques, using brachial plexus blockade, have been shown to reduce adverse effects related to opioid administration, improve patient satisfaction, and provide significantly improved analgesia immediately following these surgeries. Many medications have been investigated to extend and enhance long-acting local anesthetics' (LA) analgesic effects. Currently, dexamethasone and dexmedetomidine have been studied, looking for an optimal long-lasting single-shot nerve block. In general, adjuvants have been used in peripheral nerve blocks to accelerate onset, decrease plasmatic absorption and secondary toxic effects, and prolong the block effects. conditions: Upper Extremity Injury studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The sealed-envelope technique will be used. An assistant who is not involved in patient care will make and combine bupivacaine, whether it contains adjuvants or not. Thus, all patients, operators, and outcome assessors remain blinded to the nature of the perineural adjuvant whoMasked: PARTICIPANT count: 40 type: ESTIMATED name: Bupivacaine injection name: Bupivacaine+ Dexamethasone+ Dexmedetomidine measure: Onset of sensory block sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06356402 id: 8510224SMCPD briefTitle: An Investigation of the Efficacy of OHEM for Improving Oral Hygiene in Children overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-08 date: 2024-12 date: 2024-04-10 date: 2024-04-10 name: Ziauddin University class: OTHER name: Universiti Sains Malaysia briefSummary: This pilot study evaluates the feasibility of conducting a larger Randomized Controlled Trial to compare three oral health education delivery methods to a control group. Except for the control group, mothers in the three intervention groups will receive the same oral health education based on the OHEM module but differ in the delivery methods, namely lecture, exhibition, and demonstration. All groups will receive a booklet and oral hygiene kits and be instructed to educate their children at home. Pre- and post-intervention assessments include the satisfaction of participants, the researchers' evaluation and cost of the trial, oral hygiene status, and the knowledge of the parents and children. conditions: Dental Plaque conditions: Gingivitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: PARTICIPANT count: 540 type: ESTIMATED name: Oral Health Educational Module for Mothers (OHEM) lecture name: Oral Health Educational Module for Mothers (OHEM) exhibition name: Oral Health Educational Module for Mothers (OHEM) demonstration measure: Satisfaction of participants: measure: Recruitment and participation of participants in the study measure: Cost of the trial measure: Dental plaque scores measure: Gingival scores measure: Oral health KAP scores measure: Oral health behaviors measure: Oral health-related quality of life using Oral health impact profile-14 sex: ALL minimumAge: 12 Years maximumAge: 40 Years stdAges: CHILD stdAges: ADULT facility: Primary Healthcare Center Gulshan-e-Sikandarabad Shireen Jinnah Colony city: Karachi country: Pakistan name: Sidra Mohiuddin, MDS role: PRINCIPAL_INVESTIGATOR lat: 24.8608 lon: 67.0104 hasResults: False
<\|newrecord\|> nctId: NCT06356389 id: JX11502MA-Ib-II briefTitle: A Clinical Trial to Evaluate Safety, Tolerance and Pharmacokinetics of JX11502MA Capsule in Patients With Schizophrenia. overallStatus: COMPLETED date: 2022-03-02 date: 2022-12-27 date: 2023-01-28 date: 2024-04-10 date: 2024-04-10 name: Zhejiang Jingxin Pharmaceutical Co., Ltd. class: INDUSTRY name: Shanghai Mental Health Center briefSummary: A multicenter, randomized, double-blind, placebo-controlled, dose-increasing phase Ib/II clinical trial to evaluate the safety, tolerance and pharmacokinetic characteristics of JX11502MA capsules administered multiple times in patients with schizophrenia conditions: Schizophrenia studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Double-Blind whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 60 type: ACTUAL name: JX11502MA name: Placebo measure: Incidence of treatment-emergent adverse events (TEAEs) measure: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 28 measure: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Score at Day 28 measure: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Score at Day 28 measure: Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Day 28 measure: Tmax measure: Css_min measure: Css_max measure: Css_av measure: AUC0-t,ss measure: AUC0-∞,ss measure: AUCtau,ss measure: t1/2 sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Shanghai Mental Health Center city: Shanghai state: Shanghai zip: 201109 country: China lat: 31.22222 lon: 121.45806 hasResults: False
<\|newrecord\|> nctId: NCT06356376 id: UAarhus_AGK_MNG_2 briefTitle: The Effects of Pain and Pain Relief on Peripheral Nerve Excitability overallStatus: RECRUITING date: 2023-12-20 date: 2024-04-30 date: 2024-04-30 date: 2024-04-10 date: 2024-04-10 name: University of Aarhus class: OTHER name: Lundbeck Foundation briefSummary: This study will assess changes in nerve excitability of C-fibers, and changes in sympathetic or parasympathetic tone, when the subject experiences pain and pain relief.
The investigators will continuously measure blood pressure, heart rate, respiration rate, gastric motility, sympathetic skin response and C-fiber excitability while using thermal stimuli before and after an analgesic. conditions: Analgesia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: Heat Stimulation measure: C-fiber excitability measure: Action potential duration (ms) measure: Action potential amplitude (V) measure: Heart-rate variability (ms) measure: Blood pressure variability (mmHg) measure: Sympathetic Skin Response (V) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Danish Pain Research Center status: RECRUITING city: Aarhus N zip: 8200 country: Denmark name: Alexander G Kristensen, MD,PhD role: CONTACT phone: +45 93 52 28 64 email: alexgramm@clin.au.dk lat: 56.15674 lon: 10.21076 hasResults: False
<\|newrecord\|> nctId: NCT06356363 id: 2023_RIPH_005_OncoPREMs briefTitle: Development of a Questionnaire on Patients' Perception of Their Oncology Care Pathway (Onco-PREMs) acronym: OncoPREMs overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-11-01 date: 2025-11-01 date: 2024-04-10 date: 2024-04-10 name: Institut Jean-Godinot class: OTHER name: Université de Reims Champagne-Ardenne briefSummary: Healthcare systems are evolving, giving increasing prominence to the patient-centered model, accompanied by objective and perceived outcomes.
PREMs (Patient Reported Experience Measures) are used to assess how patients feel about their experience of care. PREMs enable patients to take an active role in their own care, and enable healthcare establishments to identify areas for improvement that can be incorporated into their quality processes.
In oncology, the collection of patient-perceived quality regarding their care pathway would enable better coordination of their care. While a few initiatives have emerged in the field of PREMs, the development of a reliable questionnaire assessing patient perception of their care pathway in oncology remains a challenge. conditions: Cancer studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 500 type: ESTIMATED name: Data collection measure: Psychometric validation sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06356350 id: IUC_jia_scoliosis_gait briefTitle: Exercise Programs on Gait in Children With Scoliosis Diagnosed JIA overallStatus: RECRUITING date: 2024-04-01 date: 2024-10-01 date: 2024-11-01 date: 2024-04-10 date: 2024-04-19 name: Istanbul University - Cerrahpasa (IUC) class: OTHER briefSummary: Juvenile Idiopathic Arthritis (JIA) is one of the common chronic diseases in childhood. Problems such as weakness or pain may occur in JIA, especially in the joints and the muscles around the trunk (1). These conditions may lead to abnormal displacement of the center of gravity, deterioration of biomechanics, and muscle imbalance in children with JIA (2, 3). All these situations can lead to scoliosis, which we often encounter in children with JIA. Current studies describing various 3-dimension (3D) exercise methods (SEAS, Schroth, Dobomed, BSPTS, Side-shift, Lyon, etc.) effective on scoliosis (4). However, no study was found in the literature that searching the effects of these exercise methods on gait parameters in children with scoliosis diagnosed JIA. conditions: Scoliosis Idiopathic conditions: Juvenile Idiopathic Arthritis conditions: Gait, Frontal studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: Conventional exercises name: 3D exercises measure: ATR measure: Cobb angle measure: Maximum Loading measure: Center of mass displacement measure: Walking speed sex: ALL minimumAge: 6 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Istanbul University-Cerrahpasa status: RECRUITING city: Istanbul country: Turkey name: Gökçe Leblebici role: CONTACT phone: 05397395718 email: leblebicigokce@gmail.com lat: 41.01384 lon: 28.94966 hasResults: False
<\|newrecord\|> nctId: NCT06356337 id: STUDY-22-01199 briefTitle: A Light Exposure Tracker Designed to Improve Circadian Rhythms - Aim 1 overallStatus: RECRUITING date: 2024-02-22 date: 2024-08-31 date: 2025-08-31 date: 2024-04-10 date: 2024-04-10 name: Icahn School of Medicine at Mount Sinai class: OTHER briefSummary: The purpose of this research study is to investigate the relationship between light and circadian rhythms. Twenty healthy older adults will be recruited to participate in a randomized, cross-over study, where an active lighting intervention designed to maintain entrainment and a control intervention designed not to entrain will be tested. conditions: Alzheimer's Disease conditions: Mild Cognitive Impairment studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 20 type: ESTIMATED name: Light goggles name: Orange glasses measure: Saliva samples for melatonin levels measure: Light exposure using the Speck measure: Sleep time using actigraphy sex: ALL minimumAge: 55 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Light and Health Research Center status: RECRUITING city: Menands state: New York zip: 12204 country: United States name: Barbara Plitnick role: CONTACT phone: 518-242-4603 email: barbara.plitnick@mountsinai.org name: Mariana Figueiro role: PRINCIPAL_INVESTIGATOR lat: 42.69202 lon: -73.72456 hasResults: False
<\|newrecord\|> nctId: NCT06356324 id: 2021-13347 briefTitle: The Effects of Music and Television on Intraoperative Hypertensive Events in Cataract Surgery overallStatus: COMPLETED date: 2021-10-18 date: 2024-01-31 date: 2024-04-01 date: 2024-04-10 date: 2024-04-10 name: Montefiore Medical Center class: OTHER briefSummary: This study investigates whether television viewing or music listening can reduce pre-operative anxiety and improve surgical outcomes for patients undergoing cataract surgery. It aims to determine the effectiveness of these interventions compared to a control group and assess their impact on physiological markers of anxiety as well as the incidence of intra-operative hypertensive events.
The key questions that are to be answered are:
1. Does watching television before cataract surgery decrease intraoperative hypertensive events and/or pre-operative anxiety in patients?
2. Does listening to music before cataract surgery decrease intraoperative hypertensive events and/or pre-operative anxiety in patients? conditions: Anxiety conditions: Intraoperative Hypertension conditions: Cataract studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants assigned to one of three groups: music listening, tv viewing, or control (waiting with ambient noise) primaryPurpose: PREVENTION masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 650 type: ACTUAL name: Music Intervention name: Television Intervention measure: Intraoperative hypertensive event measure: Change in VAS-A measurements for Anxiety measure: Change in Heart Rate measurements for Anxiety measure: Change in Blood pressure measurements for Anxiety sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Montefiore Medical Center city: New York state: New York zip: 10467 country: United States lat: 40.71427 lon: -74.00597 hasResults: False
<\|newrecord\|> nctId: NCT06356311 id: 2870-015 id: 2023-505423-31 type: REGISTRY domain: EU CT id: U1111-1291-7109 type: OTHER domain: UTN id: MK-2870-015 type: OTHER domain: Merck Id briefTitle: A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) overallStatus: NOT_YET_RECRUITING date: 2024-05-08 date: 2027-01-04 date: 2028-05-05 date: 2024-04-10 date: 2024-04-29 name: Merck Sharp & Dohme LLC class: INDUSTRY briefSummary: This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumotecan is superior to TPC with respect to Overall Survival (OS). conditions: Gastroesophageal Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 450 type: ESTIMATED name: Sacituzumab tirumotecan name: Trifluridine-Tipiracil name: Irinotecan name: Paclitaxel name: Docetaxel measure: Overall Survival (OS) measure: Progression-free survival (PFS) measure: Objective Response Rate (ORR) measure: Duration of Response (DOR) measure: Number of Participants Who Experience an Adverse Event (AE) measure: Number of Participants Who Discontinue Study Intervention Due to an AE sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06356298 id: MCHH_004 briefTitle: Flexible Reinforced Laryngeal Mask Airway Versus Endotracheal Tube for Childhood Adenotonsillectomy overallStatus: COMPLETED date: 2023-08-01 date: 2023-12-31 date: 2023-12-31 date: 2024-04-10 date: 2024-04-24 name: Maternal and Child Health Hospital of Hubei Province class: OTHER briefSummary: The goal of this clinical trial is to compare the airway management effects of flexible reinforced laryngeal mask and endotracheal tube in childhood adenotonsillectomy.
Participants will be randomly allocated to two groups: endotracheal tube group (ETT) and flexible reinforced laryngeal mask group (FLMA). For those in ETT group: they will be intubated after induction of anesthesia .For those in FLMA group: they will be put in flexible reinforced laryngeal mask after induction of anesthesia .
The investigators will compare FLMA with ETT to see if flexible reinforced laryngeal mask can be used safely and effectively in childhood adenotonsillectomy，and if there will be less severe adverse events in FLMA. conditions: Anesthesia Intubation Complication conditions: Airway conditions: Adenotonsillectomy conditions: Children studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 100 type: ACTUAL name: Airway Management: Flexible Reinforced Laryngeal Mask Airway name: Airway Management: Endotracheal Tube measure: Peak airway pressure measure: Petco2 measure: Ventilation leakage or not measure: Mean arterial pressure (MAP) measure: Heart rate (HR) measure: Recovery time measure: Extubation time measure: Dosage of anesthetic measure: Success of FLMA or ETT measure: Surgeon satisfaction measure: Adverse events sex: ALL minimumAge: 2 Years maximumAge: 10 Years stdAges: CHILD facility: Maternal and Child Health Hospital of Hubei Province city: Wuhan state: Hubei zip: 430000 country: China lat: 30.58333 lon: 114.26667 hasResults: False
<\|newrecord\|> nctId: NCT06356285 id: 6995049 briefTitle: Testing New Ways to Name Antimicrobial Resistance overallStatus: NOT_YET_RECRUITING date: 2024-04-10 date: 2024-06-01 date: 2024-06-01 date: 2024-04-10 date: 2024-04-10 name: Imperial College London class: OTHER name: The Behavioural Insights Team briefSummary: This study aims to investigate the public's views on antibiotics and the impact of different ways to name the potential consequences of antibiotics not working in the future. It is known that current ways to name this don't resonate well with the public, and the study team have worked with members of the public through focus groups and community workshops to develop new ways of describing this in a process of co-design. This study aims to test four different ways of presenting this potential crisis to the public, some of which are new communication strategies designed by the public themselves, to evaluate which are the most memorable and investigate the impact on behaviour change.
Adults aged over 18, living in the United Kingdom, who have already signed up to a market panel research company will be eligible to participate in this study.
Participants will be invited to complete a short online survey (this should take around five minutes), advertised to them by the market research panel they have already signed up to. This survey is completely anonymous, and contains some multiple-choice questions, and some that require a short free text response. At the start of the survey one of the four ways to name AMR will be presented to participants in the form of a poster.
This study aims to result in an improved understanding regarding the general public's understanding of antibiotic use and investigate the impact of communication on behaviour change. The data from this study may be used to inform future public health campaigns on this topic and improve the use of antibiotics.
This study will be conducted online using the Predictiv platform, an online platform built by the Behavioural Insights Team. The study is being run in collaboration between the Behavioural Insights Team and the Institute of Global Health Innovation at Imperial College London.
Is it anticipated that the survey will open in April 2024 and be open until recruitment of 4000 participants is complete. This is expected to take 4-6 weeks. conditions: Antimicrobial Resistance conditions: Attitude to Health studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This study has been designed as a four-armed online randomised control trial (RCT). This will be conducted using Predictiv, an online platform for running behavioural experiments built by the Behavioural Insights Team The 4,000 participants will be randomised in a 1:1:1:1 ratio to one of four trial arms. primaryPurpose: OTHER masking: SINGLE maskingDescription: Participants will be blinded to the study arm that they have been assigned to. whoMasked: PARTICIPANT count: 4000 type: ESTIMATED name: Presentation of Antimicrobial Resistance measure: Attitudes towards Antimicrobial Resistance (Sentiment) measure: Comprehension measure: Intent measure: Recall measure: Impact on population sub-groups sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06356272 id: 19-006036 id: NCI-2024-00965 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: 19-006036 type: OTHER domain: Mayo Clinic Institutional Review Board briefTitle: Oropharynx (OPX) Biomarker Trial overallStatus: RECRUITING date: 2019-11-15 date: 2024-12-15 date: 2025-12-15 date: 2024-04-10 date: 2024-04-10 name: Mayo Clinic class: OTHER briefSummary: The purpose of this research is to identify a biomarker that is exists when human papillomavirus (HPV) mediated oropharyngeal squamous cell carcinoma is present and does not exist when HPV mediated oropharyngeal squamous cell carcinoma is absent. conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 conditions: Metastatic Oropharyngeal Squamous Cell Carcinoma conditions: Oropharyngeal Squamous Cell Carcinoma conditions: Recurrent Oropharyngeal Squamous Cell Carcinoma conditions: Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 conditions: Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8 studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 180 type: ESTIMATED name: Non-Interventional Study measure: Change in biomarkers measure: Oncologic outcomes associated with biomarkers measure: Genetic alterations measure: Immunologic biomarkers for predicting progression free survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Rochester status: RECRUITING city: Rochester state: Minnesota zip: 55905 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: Diane Vogen role: CONTACT phone: 507-266-1247 email: Vogen.Diane2@mayo.edu name: Kathryn M. Van Abel, M.D. role: PRINCIPAL_INVESTIGATOR lat: 44.02163 lon: -92.4699 hasResults: False
<\|newrecord\|> nctId: NCT06356259 id: IMMUNRX-01 id: 2023-503917-31 type: EUDRACT_NUMBER briefTitle: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants overallStatus: RECRUITING date: 2023-06-07 date: 2025-01-22 date: 2025-01-22 date: 2024-04-10 date: 2024-04-15 name: ImmunoRx Pharma Inc. class: INDUSTRY briefSummary: The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics with intravenous(IV) administration of IRX-010 in Healthy Participants. conditions: Healthy Participants studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: BASIC_SCIENCE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 81 type: ESTIMATED name: IRX-010 name: Placebo measure: Number of participants with Serious Adverse Events measure: Number of participants with Treatment-Emergent Adverse Events measure: Pharmacokinetics(PK): Area under Curve(AUC) measure: Pharmacokinetics(PK): Maximum Concentration (Cmax) measure: Pharmacokinetics(PK): Half-Life (t½) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: ICON status: RECRUITING city: Groningen zip: 9728 country: Netherlands name: Renger Tiessen role: CONTACT name: Renger Tiessen role: PRINCIPAL_INVESTIGATOR lat: 53.21917 lon: 6.56667 hasResults: False
<\|newrecord\|> nctId: NCT06356246 id: APHP240363 briefTitle: Oral Health Status of Cystic Fibrosis Patients. An Online Survey in Collaboration With the Vaincre la Mucoviscidose Patient Association. acronym: E-MUCODENT overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-08-01 date: 2024-08-01 date: 2024-04-10 date: 2024-04-10 name: Assistance Publique - Hôpitaux de Paris class: OTHER name: Vaincre la Mucoviscidose briefSummary: Cystic Fibrosis (CF) is a rare hereditary disease with autosomal recessive transmission, affecting 1 in 4700 births in France. Numerous studies have explored the links between oral health and CF, predominantly focusing on a children population. These studies reveal hyposalivation, a risk of dental erosion, an increased prevalence of enamel structural defects, but a reduced prevalence of dental caries in CF children, potentially explained by better oral hygiene. Periodontal disease does not appear to be increased in this population, while the oral quality of life of CF patients has been insufficiently studied.
Today, emerging challenges arise due to the increased life expectancy of CF patients, attributed to the rise of modulators such as Kaftrio®, resulting in an adult-majority population in France. The study of periodontal diseases, associated with oral dysbiosis, becomes relevant as they represent bacterial reservoirs that could impact respiratory complications in CF patients.
To deepen understanding of the links between oral health and CF, as well as to improve oral health of these patients, it is crucial to update the specific oral profile of this population. A cross-sectional survey using a questionnaire is proposed to include a large number of CF patients in France, aiming for real-life data. This questionnaire is constructed around internationally recognized tools for comparative analysis with normative data. Collaboration with the Patients Association "Vaincre la Mucoviscidose" (VLM) facilitates questionnaire creation, dissemination, and interpretation of results. conditions: Cystic Fibrosis studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 400 type: ESTIMATED measure: Periodontal Risk Screening Score PESS measure: Assess the adherence to good oral hygiene practices and dental follow-up in adult CF patients according to French Union for Oral Health (UFSBD) 2021 measure: Evaluate the risk of dental caries and tooth wear measure: Assess the oral quality of life measure: Evaluate oral dryness sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Marjolaine GOSSET city: Ivry-sur-Seine state: Ile-de-France zip: 94270 country: France name: Marjolaine GOSSET, MD, PhD role: CONTACT phone: +33 (0)1 49 59 48 20 email: marjolaine.gosset@aphp.fr name: Anne Sophie Duflos, Vaincre La Mucoviscidose role: CONTACT phone: +33 (0)1 40 78 91 97 email: asduflos@vaincrelamuco.org lat: 48.81568 lon: 2.38487 hasResults: False
<\|newrecord\|> nctId: NCT06356233 id: FIMBEX briefTitle: Phenotyping and Identification of Biological Markers in STXBP1 Encephalopathy acronym: FIMBEX overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-10-01 date: 2027-12-31 date: 2024-04-10 date: 2024-04-10 name: Fundación Iniciativa para las Neurociencias (FINCE) class: OTHER briefSummary: This is a prospective observational study to evaluate the phenotype of 10 patients under 10 years of age with developmental epileptic encephalopathy due to mutation of the STXBP1 gene. The study will consist of a clinical and neurodevelopmental evaluation, magnetic resonance imaging, prolonged electroencephalogram, cardiological study, and analysis of biomarkers in cerebrospinal fluid. These patients will be followed up for 3 years. The aim of the study is, knowing the baseline phenotype, to analyse the response to commonly used drugs and to anticipate the response to different drugs available on the market in this group of patients based on clinical and biomarker assessment (EEG, MRI and study of specific proteins and neurotransmitters in plasma, urine and CSF). conditions: STXBP1 Encephalopathy With Epilepsy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 10 type: ESTIMATED name: No intervention will be performed measure: CSF biomarkers measure: EEG markers measure: MRI markers measure: Clinical phenotype sex: ALL minimumAge: 1 Month maximumAge: 10 Years stdAges: CHILD facility: Hospital Ruber Internacional city: Madrid zip: 28034 country: Spain name: Alvaro Beltran Corbellini, MD role: CONTACT phone: +34913875250 email: info@neurologiaclinica.es name: Antonio Gil-Nagel, MD, PhD role: CONTACT name: Antonio Gil-Nagel, MD role: PRINCIPAL_INVESTIGATOR lat: 40.4165 lon: -3.70256 hasResults: False
<\|newrecord\|> nctId: NCT06356220 id: IRB-P00046867 briefTitle: GF-NOURISH (Gluten Free Nutrition Optimization Through Ultra-processed Food Reduction and Improved Strategies for Health) acronym: GF-NOURISH overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2026-01 date: 2026-07 date: 2024-04-10 date: 2024-04-10 name: Boston Children's Hospital class: OTHER briefSummary: We propose the Gluten Free Nutrition Optimization through Ultra-processed food Reduction and Improved Strategies for Health (GF-NOURISH) study to demonstrate the feasibility and success of a nutritional education program focused on naturally occurring gluten-free foods and minimizing ultra-processed gluten-free foods. We hypothesize that nutritional educational (GF-NOURISH) intervention will have multiple health benefits conditions: Celiac Disease in Children conditions: Nutrition Disorder, Child studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 1. Study Design: Prospective randomized controlled trial.
2. Study population: Children (N=120) with newly diagnosed CeD
3. Intervention: Gluten-Free Food Guide, a nutritional education program focused on minimizing ultra-processed foods in gluten-free die(GFFG), OR a conventional GFD nutritional education class. The nutrition educational program will be based on validated GFD education program. We will use a randomized control trial to assess improvement of overall diet quality, changes in body composition, and minimize toxic and nutrient metal exposures associated with processed gluten-free foods. primaryPurpose: PREVENTION masking: NONE count: 120 type: ESTIMATED name: Gluten-Free Diet Education measure: To compare the effect of GFFG versus conventional GFD class on body composition, specifically fat free mass measure: To compare the effect of GFFG vs conventional GFD class on diet quality measure: To compare the effect of GFFG versus conventional GFD on arsenic exposure sex: ALL minimumAge: 2 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Boston Children's Hospital city: Boston state: Massachusetts zip: 02115 country: United States name: Lauren Robertson role: CONTACT name: Nan Du, MD role: PRINCIPAL_INVESTIGATOR lat: 42.35843 lon: -71.05977 hasResults: False
<\|newrecord\|> nctId: NCT06356207 id: 113-2023 briefTitle: Syncope-Asystole Latency Time in Tilt Table Test: The SALT-TILT Study acronym: SALT-TILT overallStatus: RECRUITING date: 2024-03-20 date: 2026-03 date: 2027-03 date: 2024-04-10 date: 2024-04-11 name: Azienda Ospedaliera di Bolzano class: OTHER briefSummary: Syncope is a common presenting condition. Pacemaker implantation can significantly reduce syncope recurrences in reflex syncope. However, despite careful selection, a substantial proportion of patients treated with pacemakers suffer recurrences of syncope. It is thought that a pronounced vasodepressor component may hinder the efficacy of pacing in patients, preventing adequate cerebral perfusion during the reflex, thus relativizing the anti-bradycardia function of the pacemaker to prevent syncope. It is hypothesised that the time elapsed from the actual loss of consciousness to the asystole recorded on the ECG during Tilt Table Test may be predictive in terms of response to pacemaker therapy, so this parameter becomes the subject of the present study. conditions: Syncope conditions: Pacemaker conditions: Asystole conditions: Neurally Mediated Syncope studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 64 type: ESTIMATED name: Tilt Table Test measure: SALT (Syncope-Asystole Latency Time) measure: Recurrence of syncope measure: Recurrence of syncope sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Azienda Sanitaria di Bolzano status: RECRUITING city: Bolzano zip: 39100 country: Italy name: Marco Tomaino, Dr. role: CONTACT lat: 46.49067 lon: 11.33982 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-12-06 uploadDate: 2024-04-04T15:15 filename: Prot_SAP_000.pdf size: 334779 hasResults: False
<\|newrecord\|> nctId: NCT06356194 id: AT-01B-006 briefTitle: Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2024-05-30 date: 2024-05-30 date: 2024-04-10 date: 2024-04-10 name: Atea Pharmaceuticals, Inc. class: INDUSTRY briefSummary: Drug-drug interaction study of Biktarvy and Bemnifosbuvir/Ruzasvir conditions: Healthy Volunteer Study studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 28 type: ESTIMATED name: Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK name: Cohort 2: Days 1-10 Biktarvy (BIK). Days 11-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. measure: PK of Biktarvy (BIK: Bictegravir, tenofovir alafenamide, emtricitabine) on the pharmacokinetics (PK) of Bemnifosbuvir (BEM) and Ruzasvir (RZR). measure: To determine the effect of Bemnifosbuvir (BEM)/Ruzasvir (RZR) combination on the PK of Biktarvy (BIK: Bictegravir, tenofovir alafenamide, emtricitabine) sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Atea Study Site city: Québec state: Montreal country: Canada name: Atea Study Site role: CONTACT phone: 888-481-1607 email: ateaclinicaltrials@ateapharma.com lat: 46.81228 lon: -71.21454 hasResults: False
<\|newrecord\|> nctId: NCT06356181 id: Pro00135143 briefTitle: Training Adaptations With and Without Ventilatory Training Device overallStatus: RECRUITING date: 2024-03-18 date: 2024-09-01 date: 2024-09-01 date: 2024-04-10 date: 2024-04-10 name: University of South Carolina class: OTHER name: MAXIMUS briefSummary: This project aims to assess the effectiveness of using a Respiratory Muscle Training (RMT) device during high-intensity functional training (HIFT) to improve fitness and ventilatory parameters. Primary outcome measures include aerobic, anaerobic, and HIFT measures. Secondary measures include sleep, affect, and mood state questionnaires. Participants will be randomized into one of two groups: with the RMT device and without the RMT device. conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 30 type: ESTIMATED name: Respiratory Maximus Training Device name: No Respiratory Training Device measure: Changes in spirometry measure: Changes in aerobic capacity measure: Changes in peak power measure: Changes in ventilatory threshold measure: Changes in countermovement jump measure: Changes in anaerobic capacity measure: Changes in high-intensity functional training test measure: Changes in heart rate at ventilatory threshold measure: Changes in body composition measure: Changes in sleep quality measure: Changes in total mood disturbances measure: Changes in positive mood and emotion measure: Change in blood lactate responses measure: Changes in negative mood and emotion sex: ALL minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: University of South Carolina Sport Science Lab status: RECRUITING city: Columbia state: South Carolina zip: 29208 country: United States name: Shawn M. Arent, PhD role: CONTACT phone: 803-576-8394 email: sarent@mailbox.sc.edu name: Sten O Stray-Gundersen, PhD role: CONTACT email: sten@mailbox.sc.edu lat: 34.00071 lon: -81.03481 hasResults: False
<\|newrecord\|> nctId: NCT06356168 id: SVR/IVR briefTitle: Virtual Reality in End Stage Kidney Disease overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-12-31 date: 2025-01-31 date: 2024-04-10 date: 2024-04-15 name: University of Pennsylvania class: OTHER briefSummary: The goal of this clinical trial to compare the social virtual reality and individual virtual reality in patients with end stage kidney disease who are hemodialysis. The main aim is to determine if there are differences in symptoms between the groups. Participants will use virtual reality glasses for 30-45 minutes during dialysis sessions for 4 weeks. conditions: End Stage Kidney Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: Social Virtual Reality name: Individual Virtual Reality measure: De Jong Gierveld Scale sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06356155 id: UMCC 2023.011 briefTitle: Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer acronym: NEPTUNE overallStatus: NOT_YET_RECRUITING date: 2024-10 date: 2027-07 date: 2027-07 date: 2024-04-10 date: 2024-04-10 name: University of Michigan Rogel Cancer Center class: OTHER briefSummary: This trial is a multi-site, single-arm, phase 2 trial of neoadjuvant combination of enfortumab vedotin and pembrolizumab in cisplatin-eligible patients with high-grade localized/locally advanced cT1-4 N0-1 M0 upper tract urothelial cancer who are deemed eligible for curative-intent surgery (radical nephroureterectomy or distal ureterectomy) followed by adjuvant pembrolizumab. conditions: Urothelial Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 32 type: ESTIMATED name: Enfortumab vedotin name: Pembrolizumab measure: Efficacy of the combination of enfortumab vedotin and pembrolizumab as neoadjuvant therapy in cisplatin-eligible patients based off pathological response measure: Assess the safety and toxicity of the combination of enfortumab vedotin and pembrolizumab as neoadjuvant therapy in UTUC measure: Assess whether patients who receive the combination of enfortumab vedotin and pembrolizumab as neoadjuvant therapy have increased surgical complications. measure: Estimate secondary measures of efficacy of neoadjuvant combination enfortumab vedotin and pembrolizumab and pembrolizumab adjuvant therapy (if tolerated) in response evaluable patients with UTUC by measuring RECIST v1.1 measurable disease. measure: Estimate secondary measures of efficacy of neoadjuvant combination enfortumab vedotin and pembrolizumab and pembrolizumab adjuvant therapy (if tolerated) in response evaluable patients with UTUC by measuring 2-year recurrence-free survival (RFS). measure: Estimate secondary measures of efficacy of neoadjuvant combination enfortumab vedotin and pembrolizumab and pembrolizumab adjuvant therapy (if tolerated) in response evaluable patients with UTUC by measuring 2-year overall survival (OS). measure: Estimate the number of patients who are able to complete neoadjuvant combination enfortumab vedotin and pembrolizumab and safely complete definitive surgery. measure: Assess comprehensive profiling of tumor and host characteristics (including genomics and assessment of tumor mutational burden) as predictors of response to treatment. measure: Explore circulating biomarkers as early detectors of cancer recurrence sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Michigan Comprehensive Cancer Center city: Ann Arbor state: Michigan zip: 48109 country: United States name: Irene Tsung, M.D. role: CONTACT phone: 734-936-4385 email: itsung@umich.edu name: Irene Tsung, MD role: PRINCIPAL_INVESTIGATOR lat: 42.27756 lon: -83.74088 hasResults: False
<\|newrecord\|> nctId: NCT06356142 id: UMMC-IRB-2023-317 briefTitle: The Effects of Palmar Cooling on Repeated Sprinting Ability overallStatus: NOT_YET_RECRUITING date: 2024-04-04 date: 2025-03-01 date: 2025-03-01 date: 2024-04-10 date: 2024-04-10 name: University of Mississippi Medical Center class: OTHER briefSummary: Repeated sprinting ability is key for athletic performance in a variety of sport settings. Significant degradations in work output (i.e. fatigue) have been shown to develop after just one sprinting bout1. This pilot study aims to investigate the effects that noninvasive transient temperature manipulation has on an individual's ability to perform repeated sprints. The investigators aim to enroll 90 healthy individuals, 18-30 years of age. Participants will be randomized into two groups (Group A, and B). All groups will perform a ten-minute warm-up followed by two minutes of rest. Following the warm-up and rest period, all groups will participate in a series of five sprints, 60 meters in total length with two 180 degree changes in direction. Between sprints, participants will have 10 seconds rest. After the first series of five sprints participants will be given a 2-minute rest interval. Then participants will perform another series of five sprints followed by another 2-minute rest interval. During each rest interval, Group A will utilize a palmar cooling device. Group B will utilize a placebo version of the palmar cooling device. All sprints will be timed. Heart rate recovery will be measured during all rest breaks, and a rating of perceived exertion will be measured at the beginning and end of each resting interval. Delayed onset muscle soreness will be assessed 48 hours post sprinting, utilizing a visual analog scale. conditions: Exercise Induced Fatigue studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE whoMasked: PARTICIPANT count: 90 type: ESTIMATED name: Palmar Cooling name: Placebo Palmar Cooling measure: Participants Sprinting times measure: Participants Heart Rate Recovery measure: Participants Rating of Perceived exertion measure: Participants Reported Delayed Onset Muscle Soreness sex: ALL minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT facility: University of Mississippi Medical Center city: Jackson state: Mississippi zip: 39216 country: United States name: Jacob Daniels, DPT, EdD role: CONTACT phone: 601-815-4038 email: jbdaniels@umc.edu lat: 32.29876 lon: -90.18481 hasResults: False
<\|newrecord\|> nctId: NCT06356129 id: CA073-1020 id: 2023-510178-15 type: REGISTRY domain: EU CT Number id: U1111-1300-8493 type: REGISTRY domain: UTN briefTitle: Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma acronym: GOLSEEK-1 overallStatus: NOT_YET_RECRUITING date: 2024-06-24 date: 2028-08-14 date: 2029-11-20 date: 2024-04-10 date: 2024-04-10 name: Celgene class: INDUSTRY briefSummary: The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL). conditions: Large B-cell Lymphoma studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 850 type: ESTIMATED name: Golcadomide name: Placebo name: Rituximab name: Cyclophosphamide name: Doxorubicin name: Vincristine name: Prednisone measure: Progression-free survival (PFS) assessed by the Investigator measure: Overall survival (OS) measure: Event-free survival (EFS) measure: Complete Metabolic Response assessed by the Independent Response Adjudication Committee (IRAC) measure: Minimal residual disease (MRD) negativity rate measure: Progression-free survival (PFS) assessed by the IRAC measure: Objective response (OR) assessed by the Investigator measure: Complete metabolic response (CMR) assessed by the Investigator measure: PFS24 assessed by the Investigator 24 months after randomization measure: Duration of response (DoR) measure: Second progression-free survival (PFS2) assessed by the Investigator measure: Relative dose intensity (%) measure: Time from randomization to meaningful improvement in primary domains of interest in the European Organization for Research and Treatment of Cancer - Quality of Life C30 (EORTC QLQ-C30) Questionnaire measure: Time from randomization to meaningful improvement in primary domains of interest in the Functional Assessment of Cancer Treatment-Lymphoma (FACT-LymS) Questionnaire measure: Mean change from baseline in the EORTC QLQ-C30 measure: Mean change from baseline in the FACT-LymS measure: Number of participants with Adverse Events (AEs) measure: Number of participants with treatment-emergent adverse events (TEAEs) measure: Number of participants with laboratory abnormalities measure: Number of participants with vital sign abnormalities sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Local Institution - 0014 city: Mobile state: Alabama zip: 36604 country: United States name: Site 0014 role: CONTACT lat: 30.69436 lon: -88.04305 facility: Local Institution - 0342 city: San Francisco state: California zip: 94143 country: United States name: Site 0342 role: CONTACT lat: 37.77493 lon: -122.41942 facility: Local Institution - 0287 city: Jacksonville state: Florida zip: 32224 country: United States name: Site 0287 role: CONTACT lat: 30.33218 lon: -81.65565 facility: Local Institution - 0415 city: Margate state: Florida zip: 33063 country: United States name: Site 0415 role: CONTACT lat: 26.24453 lon: -80.20644 facility: Local Institution - 0012 city: Pensacola state: Florida zip: 32504 country: United States name: Site 0012 role: CONTACT lat: 30.42131 lon: -87.21691 facility: Local Institution - 0414 city: Tampa state: Florida zip: 33612 country: United States name: Site 0414 role: CONTACT lat: 27.94752 lon: -82.45843 facility: Local Institution - 0303 city: Atlanta state: Georgia zip: 30322 country: United States name: Site 0303 role: CONTACT lat: 33.749 lon: -84.38798 facility: Local Institution - 0182 city: Chicago state: Illinois zip: 60611 country: United States name: Site 0182 role: CONTACT lat: 41.85003 lon: -87.65005 facility: Local Institution - 0048 city: Skokie state: Illinois zip: 60077 country: United States name: Site 0048 role: CONTACT lat: 42.03336 lon: -87.73339 facility: Local Institution - 0461 city: Des Moines state: Iowa zip: 50309 country: United States name: Site 0461 role: CONTACT lat: 41.60054 lon: -93.60911 facility: Local Institution - 0031 city: Fairway state: Kansas zip: 66205 country: United States name: Site 0031 role: CONTACT lat: 39.02223 lon: -94.6319 facility: Local Institution - 0436 city: Edgewood state: Kentucky zip: 41017 country: United States name: Site 0436 role: CONTACT lat: 39.01867 lon: -84.58189 facility: Local Institution - 0408 city: Baton Rouge state: Louisiana zip: 70809 country: United States name: Site 0408 role: CONTACT lat: 30.45075 lon: -91.15455 facility: Local Institution - 0067 city: Minneapolis state: Minnesota zip: 55407 country: United States name: Site 0067 role: CONTACT lat: 44.97997 lon: -93.26384 facility: Local Institution - 0203 city: Rochester state: Minnesota zip: 55905 country: United States name: Site 0203 role: CONTACT lat: 44.02163 lon: -92.4699 facility: Local Institution - 0437 city: Kansas City state: Missouri zip: 64132 country: United States name: Site 0437 role: CONTACT lat: 39.09973 lon: -94.57857 facility: Local Institution - 0466 city: Reno state: Nevada zip: 89511 country: United States name: Site 0466 role: CONTACT lat: 39.52963 lon: -119.8138 facility: Local Institution - 0049 city: Morristown state: New Jersey zip: 07960 country: United States name: Site 0049 role: CONTACT lat: 40.79677 lon: -74.48154 facility: Local Institution - 0190 city: Buffalo state: New York zip: 14263 country: United States name: Site 0190 role: CONTACT lat: 42.88645 lon: -78.87837 facility: Local Institution - 0369 city: New York state: New York zip: 10028 country: United States name: Site 0369 role: CONTACT lat: 40.71427 lon: -74.00597 facility: Local Institution - 0176 city: New York state: New York zip: 10029 country: United States name: Site 0176 role: CONTACT lat: 40.71427 lon: -74.00597 facility: Local Institution - 0174 city: Chapel Hill state: North Carolina zip: 27599 country: United States name: Site 0174 role: CONTACT lat: 35.9132 lon: -79.05584 facility: Local Institution - 0066 city: Massillon state: Ohio zip: 44646 country: United States name: Site 0066 role: CONTACT lat: 40.79672 lon: -81.52151 facility: Local Institution - 0179 city: Portland state: Oregon zip: 97239 country: United States name: Site 0179 role: CONTACT lat: 45.52345 lon: -122.67621 facility: Local Institution - 0009 city: Pittsburgh state: Pennsylvania zip: 15232 country: United States name: Site 0009 role: CONTACT lat: 40.44062 lon: -79.99589 facility: Local Institution - 0419 city: York state: Pennsylvania zip: 17403 country: United States name: Site 0419 role: CONTACT lat: 39.9626 lon: -76.72774 facility: Local Institution - 0435 city: Fort Sam Houston state: Texas zip: 78234 country: United States name: Site 0435 role: CONTACT lat: 29.45746 lon: -98.4472 facility: Local Institution - 0046 city: Houston state: Texas zip: 77030 country: United States name: Site 0046 role: CONTACT lat: 29.76328 lon: -95.36327 facility: Local Institution - 0424 city: Houston state: Texas zip: 77030 country: United States name: Site 0424 role: CONTACT lat: 29.76328 lon: -95.36327 facility: Local Institution - 0293 city: Richmond state: Virginia zip: 23219 country: United States name: Site 0293 role: CONTACT lat: 37.55376 lon: -77.46026 facility: Local Institution - 0113 city: Buenos Aires state: Ciudad Autónoma De Buenos Aires zip: C1118AAT country: Argentina name: Site 0113 role: CONTACT lat: -34.61315 lon: -58.37723 facility: Local Institution - 0421 city: Buenos Aires state: Ciudad Autónoma De Buenos Aires zip: C1417DTB country: Argentina name: Site 0421 role: CONTACT lat: -34.61315 lon: -58.37723 facility: Local Institution - 0112 city: Buenos Aires zip: 1426 country: Argentina name: Site 0112 role: CONTACT lat: -34.61315 lon: -58.37723 facility: Local Institution - 0136 city: Buenos Aires zip: C1431FWO country: Argentina name: Site 0136 role: CONTACT lat: -34.61315 lon: -58.37723 facility: Local Institution - 0119 city: Ciudad Autónoma de Buenos Aires zip: C1426ANZ country: Argentina name: Site 0119 role: CONTACT lat: -34.61315 lon: -58.37723 facility: Local Institution - 0111 city: Córdoba zip: 5016 country: Argentina name: Site 0111 role: CONTACT lat: -31.4135 lon: -64.18105 facility: Local Institution - 0357 city: Gosford state: New South Wales zip: 2250 country: Australia name: Site 0357 role: CONTACT lat: -33.4244 lon: 151.34399 facility: Local Institution - 0361 city: Sydney state: New South Wales zip: 2560 country: Australia name: Site 0361 role: CONTACT lat: -33.86785 lon: 151.20732 facility: Local Institution - 0358 city: Westmead state: New South Wales zip: 2145 country: Australia name: Site 0358 role: CONTACT lat: -33.80383 lon: 150.98768 facility: Local Institution - 0363 city: Tiwi state: Northern Territory zip: 0810 country: Australia name: Site 0363 role: CONTACT lat: -12.35876 lon: 130.878 facility: Local Institution - 0356 city: Birtinya state: Queensland zip: 4575 country: Australia name: Site 0356 role: CONTACT lat: -26.74322 lon: 153.11913 facility: Local Institution - 0360 city: Southport state: Queensland zip: 4215 country: Australia name: Site 0360 role: CONTACT lat: -27.96724 lon: 153.39796 facility: Local Institution - 0365 city: Frankston state: Victoria zip: 3195 country: Australia name: Site 0365 role: CONTACT lat: -38.14458 lon: 145.12291 facility: Local Institution - 0362 city: Heidelberg state: Victoria zip: 3084 country: Australia name: Site 0362 role: CONTACT lat: -37.75 lon: 145.06667 facility: Local Institution - 0359 city: St Albans state: Victoria zip: 3021 country: Australia name: Site 0359 role: CONTACT lat: -37.73901 lon: 144.80024 facility: Local Institution - 0364 city: Warrnambool state: Victoria zip: 3280 country: Australia name: Site 0364 role: CONTACT lat: -38.38176 lon: 142.48799 facility: Local Institution - 0385 city: Wels state: Oberösterreich zip: 4600 country: Austria name: Site 0385 role: CONTACT lat: 48.16667 lon: 14.03333 facility: Local Institution - 0387 city: Linz zip: 4021 country: Austria name: Site 0387 role: CONTACT lat: 48.30639 lon: 14.28611 facility: Local Institution - 0386 city: Vienna zip: 1140 country: Austria name: Site 0386 role: CONTACT lat: 48.20849 lon: 16.37208 facility: Local Institution - 0255 city: Fortaleza state: Ceará zip: 60115-281 country: Brazil name: Site 0255 role: CONTACT lat: -3.71722 lon: -38.54306 facility: Local Institution - 0297 city: Lago sul state: Distrito Federal zip: 71635580 country: Brazil name: Site 0297 role: CONTACT lat: -15.90603 lon: -47.86366 facility: Local Institution - 0256 city: Goiania state: Goiás zip: 74605-020 country: Brazil name: Site 0256 role: CONTACT lat: -16.67861 lon: -49.25389 facility: Local Institution - 0302 city: Curitiba state: Paraná zip: 81520-060 country: Brazil name: Site 0302 role: CONTACT lat: -25.42778 lon: -49.27306 facility: Local Institution - 0296 city: Niteroi state: Rio De Janeiro zip: 24020-096 country: Brazil name: Site 0296 role: CONTACT lat: -22.88333 lon: -43.10361 facility: Local Institution - 0304 city: Natal state: Rio Grande Do Norte zip: 59075-740 country: Brazil name: Site 0304 role: CONTACT lat: -5.795 lon: -35.20944 facility: Local Institution - 0253 city: Porto Alegre state: Rio Grande Do Sul zip: 90110-270 country: Brazil name: Site 0253 role: CONTACT lat: -30.03306 lon: -51.23 facility: Local Institution - 0246 city: Chapecó state: Santa Catarina zip: 89812-211 country: Brazil name: Site 0246 role: CONTACT lat: -27.09639 lon: -52.61833 facility: Local Institution - 0247 city: Joinville state: Santa Catarina zip: 89201260 country: Brazil name: Site 0247 role: CONTACT lat: -26.30444 lon: -48.84556 facility: Local Institution - 0250 city: Barretos state: São Paulo zip: 14784400 country: Brazil name: Site 0250 role: CONTACT lat: -20.55722 lon: -48.56778 facility: Local Institution - 0249 city: Jaú state: São Paulo zip: 17210-120 country: Brazil name: Site 0249 role: CONTACT lat: -22.29639 lon: -48.55778 facility: Local Institution - 0248 city: Sao Paulo state: São Paulo zip: 01323-903 country: Brazil name: Site 0248 role: CONTACT lat: -23.5475 lon: -46.63611 facility: Local Institution - 0316 city: Sao Paulo state: São Paulo zip: 01509-010 country: Brazil name: Site 0316 role: CONTACT lat: -23.5475 lon: -46.63611 facility: Local Institution - 0252 city: Sao Paulo state: São Paulo zip: 04543-000 country: Brazil name: Site 0252 role: CONTACT lat: -23.5475 lon: -46.63611 facility: Local Institution - 0301 city: São José do Rio Preto state: São Paulo zip: 15090000 country: Brazil name: Site 0301 role: CONTACT lat: -20.81972 lon: -49.37944 facility: Local Institution - 0298 city: Rio de Janeiro zip: 22061-080 country: Brazil name: Site 0298 role: CONTACT lat: -22.90278 lon: -43.2075 facility: Local Institution - 0294 city: São Paulo zip: 01409-902 country: Brazil name: Site 0294 role: CONTACT lat: -23.5475 lon: -46.63611 facility: Local Institution - 0251 city: São Paulo zip: 05652-900 country: Brazil name: Site 0251 role: CONTACT lat: -23.5475 lon: -46.63611 facility: Local Institution - 0394 city: Sofia state: Sofia (stolitsa) zip: 1431 country: Bulgaria name: Site 0394 role: CONTACT lat: 42.69751 lon: 23.32415 facility: Local Institution - 0393 city: Plovdiv zip: 4002 country: Bulgaria name: Site 0393 role: CONTACT lat: 42.15 lon: 24.75 facility: Local Institution - 0392 city: Sofia zip: 1407 country: Bulgaria name: Site 0392 role: CONTACT lat: 42.69751 lon: 23.32415 facility: Local Institution - 0091 city: Victoria state: British Columbia zip: V8R 6V5 country: Canada name: Site 0091 role: CONTACT lat: 48.43294 lon: -123.3693 facility: Local Institution - 0153 city: Montreal state: Quebec zip: H3T 1M5 country: Canada name: Site 0153 role: CONTACT lat: 45.50884 lon: -73.58781 facility: Local Institution - 0073 city: Montreal state: Quebec zip: H4J 1C5 country: Canada name: Site 0073 role: CONTACT lat: 45.50884 lon: -73.58781 facility: Local Institution - 0004 city: Sherbrooke state: Quebec zip: J1H 5N4 country: Canada name: Site 0004 role: CONTACT lat: 45.40008 lon: -71.89908 facility: Local Institution - 0109 city: Chile state: Región Metropolitana De Santiago zip: 8380455 country: Chile name: Site 0109 role: CONTACT facility: Local Institution - 0106 city: Santiago state: Región Metropolitana De Santiago zip: 7500921 country: Chile name: Site 0106 role: CONTACT lat: -33.45694 lon: -70.64827 facility: Local Institution - 0107 city: Santiago state: Región Metropolitana De Santiago zip: 7580206 country: Chile name: Site 0107 role: CONTACT lat: -33.45694 lon: -70.64827 facility: Local Institution - 0110 city: Santiago state: Región Metropolitana De Santiago zip: 8320325 country: Chile name: Site 0110 role: CONTACT lat: -33.45694 lon: -70.64827 facility: Local Institution - 0108 city: Santiago state: Región Metropolitana De Santiago zip: 8330032 country: Chile name: Site 0108 role: CONTACT lat: -33.45694 lon: -70.64827 facility: Local Institution - 0164 city: Viña del Mar state: Valparaíso zip: 0 country: Chile name: Site 0164 role: CONTACT lat: -33.02457 lon: -71.55183 facility: Local Institution - 0195 city: Beijing state: Beijing zip: 100091 country: China name: Site 0195 role: CONTACT lat: 39.9075 lon: 116.39723 facility: Local Institution - 0236 city: Chongqing state: Chongqing zip: 400016 country: China name: Site 0236 role: CONTACT lat: 29.56278 lon: 106.55278 facility: Local Institution - 0196 city: Chongqing state: Chongqing zip: 400030 country: China name: Site 0196 role: CONTACT lat: 29.56278 lon: 106.55278 facility: Local Institution - 0274 city: Fuzhou state: Fujian zip: 350014 country: China name: Site 0274 role: CONTACT lat: 26.06139 lon: 119.30611 facility: Local Institution - 0157 city: Xiamen state: Fujian zip: 361003 country: China name: Site 0157 role: CONTACT lat: 24.47979 lon: 118.08187 facility: Local Institution - 0133 city: Guangzhou state: Guangdong zip: 510515 country: China name: Site 0133 role: CONTACT lat: 23.11667 lon: 113.25 facility: Local Institution - 0240 city: Guangzhou state: Guangdong zip: 510555 country: China name: Site 0240 role: CONTACT lat: 23.11667 lon: 113.25 facility: Local Institution - 0338 city: Nanning state: Guangxi zip: 530021 country: China name: Site 0338 role: CONTACT lat: 22.81667 lon: 108.31667 facility: Local Institution - 0239 city: Harbin state: Heilongjiang zip: 150081 country: China name: Site 0239 role: CONTACT lat: 45.75 lon: 126.65 facility: Local Institution - 0238 city: Zhengzhou state: Henan zip: 450008 country: China name: Site 0238 role: CONTACT lat: 34.75778 lon: 113.64861 facility: Local Institution - 0346 city: Wuhan state: Hubei zip: 430022 country: China name: Site 0346 role: CONTACT lat: 30.58333 lon: 114.26667 facility: Local Institution - 0214 city: Wuhan state: Hubei zip: 430030 country: China name: Site 0214 role: CONTACT lat: 30.58333 lon: 114.26667 facility: Local Institution - 0275 city: Changsha state: Hunan zip: 410013 country: China name: Site 0275 role: CONTACT lat: 28.19874 lon: 112.97087 facility: Local Institution - 0156 city: Suzhou state: Jiangsu zip: 215006 country: China name: Site 0156 role: CONTACT lat: 31.30408 lon: 120.59538 facility: Local Institution - 0237 city: Nanchang state: Jiangxi zip: 330006 country: China name: Site 0237 role: CONTACT lat: 28.68396 lon: 115.85306 facility: Local Institution - 0241 city: Nanchang state: Jiangxi zip: 330029 country: China name: Site 0241 role: CONTACT lat: 28.68396 lon: 115.85306 facility: Local Institution - 0291 city: Changchun state: Jilin zip: 130021 country: China name: Site 0291 role: CONTACT lat: 43.88 lon: 125.32278 facility: Local Institution - 0334 city: Shenyang state: Liaoning zip: 110004 country: China name: Site 0334 role: CONTACT lat: 41.79222 lon: 123.43278 facility: Local Institution - 0169 city: Shenyang state: Liaoning zip: 110015 country: China name: Site 0169 role: CONTACT lat: 41.79222 lon: 123.43278 facility: Local Institution - 0242 city: Jinan state: Shandong zip: 250012 country: China name: Site 0242 role: CONTACT lat: 36.66833 lon: 116.99722 facility: Local Institution - 0344 city: Jinan state: Shandong zip: 250117 country: China name: Site 0344 role: CONTACT lat: 36.66833 lon: 116.99722 facility: Local Institution - 0132 city: Shanghai state: Shanghai zip: 200025 country: China name: Site 0132 role: CONTACT lat: 31.22222 lon: 121.45806 facility: Local Institution - 0339 city: Shanghai state: Shanghai zip: 200032 country: China name: Site 0339 role: CONTACT lat: 31.22222 lon: 121.45806 facility: Local Institution - 0234 city: Taiyuan state: Shanxi zip: 030032 country: China name: Site 0234 role: CONTACT lat: 37.86944 lon: 112.56028 facility: Local Institution - 0141 city: Cheng Du state: Sichuan zip: 610041 country: China name: Site 0141 role: CONTACT facility: Local Institution - 0289 city: Tianjin state: Tianjin zip: 300020 country: China name: Site 0289 role: CONTACT lat: 39.14222 lon: 117.17667 facility: Local Institution - 0155 city: Urumchi state: Xinjiang zip: 830054 country: China name: Site 0155 role: CONTACT facility: Local Institution - 0197 city: Hangzhou state: Zhejiang zip: 310003 country: China name: Site 0197 role: CONTACT lat: 30.29365 lon: 120.16142 facility: Local Institution - 0457 city: Wenzhou state: Zhejiang zip: 325000 country: China name: Site 0457 role: CONTACT lat: 27.99942 lon: 120.66682 facility: Local Institution - 0130 city: Bogota state: Cundinamarca zip: 111151 country: Colombia name: Site 0130 role: CONTACT lat: 4.60971 lon: -74.08175 facility: Local Institution - 0129 city: Bogotá state: Distrito Capital De Bogotá zip: 110131 country: Colombia name: Site 0129 role: CONTACT lat: 4.60971 lon: -74.08175 facility: Local Institution - 0390 city: Zagreb state: Grad Zagreb zip: 10000 country: Croatia name: Site 0390 role: CONTACT lat: 45.81444 lon: 15.97798 facility: Local Institution - 0440 city: Osijek zip: 31000 country: Croatia name: Site 0440 role: CONTACT lat: 45.55111 lon: 18.69389 facility: Local Institution - 0105 city: Brno state: Brno-město zip: 625 00 country: Czechia name: Site 0105 role: CONTACT lat: 49.19522 lon: 16.60796 facility: Local Institution - 0104 city: Hradec Kralove state: Hradec Králové zip: 500 05 country: Czechia name: Site 0104 role: CONTACT lat: 50.20923 lon: 15.83277 facility: Local Institution - 0102 city: Olomouc state: Olomoucký Kraj zip: 779 00 country: Czechia name: Site 0102 role: CONTACT lat: 49.59552 lon: 17.25175 facility: Local Institution - 0120 city: Pilsen state: Plzeňský Kraj zip: 305 99 country: Czechia name: Site 0120 role: CONTACT lat: 49.74747 lon: 13.37759 facility: Local Institution - 0103 city: PRague state: Praha 10 zip: 100 34 country: Czechia name: Site 0103 role: CONTACT lat: 50.08804 lon: 14.42076 facility: Local Institution - 0243 city: Praha 2 zip: 12808 country: Czechia name: Site 0243 role: CONTACT lat: 50.08804 lon: 14.42076 facility: Local Institution - 0285 city: Aarhus state: Midtjylland zip: 8200 country: Denmark name: Site 0285 role: CONTACT lat: 56.15674 lon: 10.21076 facility: Local Institution - 0284 city: Odense state: Syddanmark zip: 5000 country: Denmark name: Site 0284 role: CONTACT lat: 55.39594 lon: 10.38831 facility: Local Institution - 0281 city: Oulu state: Pohjois-Pohjanmaa zip: 90220 country: Finland name: Site 0281 role: CONTACT lat: 65.01236 lon: 25.46816 facility: Local Institution - 0283 city: Kuopio state: Pohjois-Savo zip: 70210 country: Finland name: Site 0283 role: CONTACT lat: 62.89238 lon: 27.67703 facility: Local Institution - 0282 city: Turku state: Varsinais-Suomi zip: 20521 country: Finland name: Site 0282 role: CONTACT lat: 60.45148 lon: 22.26869 facility: Local Institution - 0280 city: Helsinki zip: 00029 country: Finland name: Site 0280 role: CONTACT lat: 60.16952 lon: 24.93545 facility: Local Institution - 0083 city: Nice state: Alpes-Maritimes zip: 06202 country: France name: Site 0083 role: CONTACT lat: 43.70313 lon: 7.26608 facility: Local Institution - 0084 city: Strasbourg state: Alsace zip: 67033 country: France name: Site 0084 role: CONTACT lat: 48.58392 lon: 7.74553 facility: Local Institution - 0090 city: Bordeaux state: Aquitaine zip: 33076 country: France name: Site 0090 role: CONTACT lat: 44.84044 lon: -0.5805 facility: Local Institution - 0324 city: Pessac state: Aquitaine zip: 33600 country: France name: Site 0324 role: CONTACT lat: 44.81011 lon: -0.64129 facility: Local Institution - 0087 city: Marseille state: Bouches-du-Rhône zip: 13273 country: France name: Site 0087 role: CONTACT lat: 43.29551 lon: 5.38958 facility: Local Institution - 0292 city: Dijon state: Côte-d'Or zip: 21000 country: France name: Site 0292 role: CONTACT lat: 47.31667 lon: 5.01667 facility: Local Institution - 0332 city: Brest state: Finistère zip: 29609 country: France name: Site 0332 role: CONTACT lat: 48.3903 lon: -4.48628 facility: Local Institution - 0335 city: Saint-Cloud state: Hauts-de-Seine zip: 92210 country: France name: Site 0335 role: CONTACT lat: 48.84598 lon: 2.20289 facility: Local Institution - 0079 city: Tours state: Indre-et-Loire zip: 37032 country: France name: Site 0079 role: CONTACT lat: 47.38333 lon: 0.68333 facility: Local Institution - 0321 city: Saint Priest en Jarez state: Loire zip: 42271 country: France name: Site 0321 role: CONTACT lat: 45.47501 lon: 4.37614 facility: Local Institution - 0081 city: Lille state: Nord zip: 59000 country: France name: Site 0081 role: CONTACT lat: 50.63297 lon: 3.05858 facility: Local Institution - 0325 city: Nantes state: Pays-de-la-Loire zip: 44000 country: France name: Site 0325 role: CONTACT lat: 47.21725 lon: -1.55336 facility: Local Institution - 0089 city: Pierre-Bénite state: Rhône zip: 69310 country: France name: Site 0089 role: CONTACT lat: 45.7009 lon: 4.82511 facility: Local Institution - 0200 city: Creteil state: Val-de-Marne zip: 94010 country: France name: Site 0200 role: CONTACT lat: 48.78333 lon: 2.46667 facility: Local Institution - 0076 city: Villejuif state: Val-de-Marne zip: 94805 country: France name: Site 0076 role: CONTACT lat: 48.7939 lon: 2.35992 facility: Local Institution - 0306 city: Poitiers state: Vienne zip: 86021 country: France name: Site 0306 role: CONTACT lat: 46.58333 lon: 0.33333 facility: Local Institution - 0244 city: Bayonne zip: 64109 country: France name: Site 0244 role: CONTACT lat: 43.48333 lon: -1.48333 facility: Local Institution - 0315 city: Caen zip: 14033 country: France name: Site 0315 role: CONTACT lat: 49.18585 lon: -0.35912 facility: Local Institution - 0202 city: Lille zip: 59020 country: France name: Site 0202 role: CONTACT lat: 50.63297 lon: 3.05858 facility: Local Institution - 0077 city: Paris zip: 75010 country: France name: Site 0077 role: CONTACT lat: 48.85341 lon: 2.3488 facility: Local Institution - 0323 city: Saint-Pierre zip: 97448 country: France name: Site 0323 role: CONTACT facility: Local Institution - 0383 city: Augsburg state: Bayern zip: 86156 country: Germany name: Site 0383 role: CONTACT lat: 48.37154 lon: 10.89851 facility: Local Institution - 0384 city: Koblenz state: Rheinland-Pfalz zip: 56068 country: Germany name: Site 0384 role: CONTACT lat: 50.35357 lon: 7.57883 facility: Local Institution - 0370 city: Essen zip: 45122 country: Germany name: Site 0370 role: CONTACT lat: 51.45657 lon: 7.01228 facility: Local Institution - 0399 city: Athens state: Attikí zip: 106 76 country: Greece name: Site 0399 role: CONTACT lat: 37.97945 lon: 23.71622 facility: Local Institution - 0396 city: Athens state: Attikí zip: 11527 country: Greece name: Site 0396 role: CONTACT lat: 37.97945 lon: 23.71622 facility: Local Institution - 0397 city: Chaidari state: Attikí zip: 12462 country: Greece name: Site 0397 role: CONTACT lat: 38.01135 lon: 23.66597 facility: Local Institution - 0398 city: Alexandroupolis zip: 08100 country: Greece name: Site 0398 role: CONTACT lat: 40.84995 lon: 25.87644 facility: Local Institution - 0395 city: Ioannina state: Ípeiros zip: 455 00 country: Greece name: Site 0395 role: CONTACT lat: 39.66486 lon: 20.85189 facility: Local Institution - 0160 city: Budapest state: Pest zip: 1122 country: Hungary name: Site 0160 role: CONTACT lat: 47.49801 lon: 19.03991 facility: Local Institution - 0162 city: Kaposvár state: Somogy zip: 7400 country: Hungary name: Site 0162 role: CONTACT lat: 46.36667 lon: 17.8 facility: Local Institution - 0353 city: Nyiregyhaza state: Szabolcs-Szatmár-Bereg zip: 4400 country: Hungary name: Site 0353 role: CONTACT lat: 47.95539 lon: 21.71671 facility: Local Institution - 0161 city: Szombathely state: Vas zip: 9700 country: Hungary name: Site 0161 role: CONTACT lat: 47.23088 lon: 16.62155 facility: Local Institution - 0163 city: Budapest zip: 1088 country: Hungary name: Site 0163 role: CONTACT lat: 47.49801 lon: 19.03991 facility: Local Institution - 0266 city: Debrecen zip: 4032 country: Hungary name: Site 0266 role: CONTACT lat: 47.53333 lon: 21.63333 facility: Local Institution - 0276 city: Anjo state: Aichi zip: 446-8602 country: Japan name: Site 0276 role: CONTACT lat: 34.95828 lon: 137.08054 facility: Local Institution - 0371 city: Nagoya state: Aichi zip: 466-8560 country: Japan name: Site 0371 role: CONTACT lat: 35.18147 lon: 136.90641 facility: Local Institution - 0168 city: Kashiwa state: Chiba zip: 277-8577 country: Japan name: Site 0168 role: CONTACT lat: 35.86224 lon: 139.97732 facility: Local Institution - 0271 city: Ogaki state: Gifu zip: 503-0864 country: Japan name: Site 0271 role: CONTACT lat: 35.35 lon: 136.61667 facility: Local Institution - 0368 city: Sapporo state: Hokkaido zip: 0608648 country: Japan name: Site 0368 role: CONTACT lat: 43.06667 lon: 141.35 facility: Local Institution - 0327 city: Sapporo state: Hokkaido zip: 064-0804 country: Japan name: Site 0327 role: CONTACT lat: 43.06667 lon: 141.35 facility: Local Institution - 0273 city: Amagasaki state: Hyogo zip: 660-8550 country: Japan name: Site 0273 role: CONTACT lat: 34.71667 lon: 135.41667 facility: Local Institution - 0328 city: Himeji state: Hyogo zip: 670-8540 country: Japan name: Site 0328 role: CONTACT lat: 34.81667 lon: 134.7 facility: Local Institution - 0270 city: Kanazawa state: Ishikawa zip: 920-8530 country: Japan name: Site 0270 role: CONTACT lat: 36.6 lon: 136.61667 facility: Local Institution - 0343 city: Morioka state: Iwate zip: 020-0066 country: Japan name: Site 0343 role: CONTACT lat: 39.7 lon: 141.15 facility: Local Institution - 0170 city: Isehara state: Kanagawa zip: 259-1193 country: Japan name: Site 0170 role: CONTACT lat: 35.39932 lon: 139.31019 facility: Local Institution - 0333 city: Yokohama state: Kanagawa zip: 221-0855 country: Japan name: Site 0333 role: CONTACT lat: 35.43333 lon: 139.65 facility: Local Institution - 0320 city: Sendai-shi state: Miyagi zip: 980-8574 country: Japan name: Site 0320 role: CONTACT lat: 38.26667 lon: 140.86667 facility: Local Institution - 0166 city: Osaka-sayama state: Osaka zip: 589-8511 country: Japan name: Site 0166 role: CONTACT lat: 34.69374 lon: 135.50218 facility: Local Institution - 0269 city: Hidaka state: Saitama zip: 350-1298 country: Japan name: Site 0269 role: CONTACT facility: Local Institution - 0288 city: Nagaizumi-cho,Sunto-gun state: Shizuoka zip: 411-8777 country: Japan name: Site 0288 role: CONTACT facility: Local Institution - 0350 city: Bunkyo-ku state: Tokyo zip: 113-8431 country: Japan name: Site 0350 role: CONTACT lat: 35.37517 lon: 139.92991 facility: Local Institution - 0268 city: Itabashiku state: Tokyo zip: 173-8610 country: Japan name: Site 0268 role: CONTACT facility: Local Institution - 0331 city: Chuo state: Yamanashi zip: 409-3898 country: Japan name: Site 0331 role: CONTACT lat: 35.57779 lon: 139.71685 facility: Local Institution - 0348 city: Fukuoka zip: 810-8563 country: Japan name: Site 0348 role: CONTACT lat: 33.6 lon: 130.41667 facility: Local Institution - 0319 city: Fukuoka zip: 811-1395 country: Japan name: Site 0319 role: CONTACT lat: 33.6 lon: 130.41667 facility: Local Institution - 0313 city: Fukuoka zip: 812-8582 country: Japan name: Site 0313 role: CONTACT lat: 33.6 lon: 130.41667 facility: Local Institution - 0272 city: Hiroshima zip: 734-8551 country: Japan name: Site 0272 role: CONTACT lat: 34.4 lon: 132.45 facility: Local Institution - 0171 city: Kumamoto zip: 860-0008 country: Japan name: Site 0171 role: CONTACT lat: 32.80589 lon: 130.69182 facility: Local Institution - 0215 city: Kyoto zip: 602-8566 country: Japan name: Site 0215 role: CONTACT lat: 35.02107 lon: 135.75385 facility: Local Institution - 0329 city: Okayama zip: 700-8558 country: Japan name: Site 0329 role: CONTACT lat: 34.65 lon: 133.93333 facility: Local Institution - 0322 city: Osaka zip: 543-8555 country: Japan name: Site 0322 role: CONTACT lat: 34.69374 lon: 135.50218 facility: Local Institution - 0347 city: Osaka zip: 545-8586 country: Japan name: Site 0347 role: CONTACT lat: 34.69374 lon: 135.50218 facility: Local Institution - 0167 city: Yamagata zip: 990-9585 country: Japan name: Site 0167 role: CONTACT lat: 38.23333 lon: 140.36667 facility: Local Institution - 0149 city: Goyang-si state: Kyǒnggi-do zip: 10408 country: Korea, Republic of name: Site 0149 role: CONTACT lat: 37.65639 lon: 126.835 facility: Local Institution - 0117 city: Seongnam state: Kyǒnggi-do zip: 13620 country: Korea, Republic of name: Site 0117 role: CONTACT lat: 37.43861 lon: 127.13778 facility: Local Institution - 0233 city: Suwon-si state: Kyǒnggi-do zip: 16499 country: Korea, Republic of name: Site 0233 role: CONTACT lat: 37.29111 lon: 127.00889 facility: Local Institution - 0115 city: Busan state: Pusan-Kwangyǒkshi zip: 49201 country: Korea, Republic of name: Site 0115 role: CONTACT lat: 35.10278 lon: 129.04028 facility: Local Institution - 0114 city: Busan state: Pusan-Kwangyǒkshi zip: 49241 country: Korea, Republic of name: Site 0114 role: CONTACT lat: 35.10278 lon: 129.04028 facility: Local Institution - 0131 city: Busan state: Pusan-Kwangyǒkshi zip: 49267 country: Korea, Republic of name: Site 0131 role: CONTACT lat: 35.10278 lon: 129.04028 facility: Local Institution - 0143 city: Seoul state: Seoul-teukbyeolsi [Seoul] zip: 02841 country: Korea, Republic of name: Site 0143 role: CONTACT lat: 37.566 lon: 126.9784 facility: Local Institution - 0069 city: Seoul state: Seoul-teukbyeolsi [Seoul] zip: 03080 country: Korea, Republic of name: Site 0069 role: CONTACT lat: 37.566 lon: 126.9784 facility: Local Institution - 0100 city: Seoul state: Seoul-teukbyeolsi [Seoul] zip: 05505 country: Korea, Republic of name: Site 0100 role: CONTACT lat: 37.566 lon: 126.9784 facility: Local Institution - 0068 city: Seoul state: Seoul-teukbyeolsi [Seoul] zip: 06351 country: Korea, Republic of name: Site 0068 role: CONTACT lat: 37.566 lon: 126.9784 facility: Local Institution - 0070 city: Seoul state: Seoul-teukbyeolsi [Seoul] zip: 06591 country: Korea, Republic of name: Site 0070 role: CONTACT lat: 37.566 lon: 126.9784 facility: Local Institution - 0118 city: Seoul state: Seoul-teukbyeolsi [Seoul] zip: 07345 country: Korea, Republic of name: Site 0118 role: CONTACT lat: 37.566 lon: 126.9784 facility: Local Institution - 0442 city: Daegu state: Taegu-Kwangyǒkshi zip: 41404 country: Korea, Republic of lat: 35.87028 lon: 128.59111 facility: Local Institution - 0116 city: Deagu state: Taegu-Kwangyǒkshi zip: 41404 country: Korea, Republic of facility: Local Institution - 0455 city: Seongnam zip: 463-707 country: Korea, Republic of lat: 37.43861 lon: 127.13778 facility: Local Institution - 0432 city: George Town state: Pulau Pinang zip: 10990 country: Malaysia name: Site 0432 role: CONTACT lat: 5.41123 lon: 100.33543 facility: Local Institution - 0431 city: Kuching state: Sarawak zip: 93586 country: Malaysia name: Site 0431 role: CONTACT lat: 1.54999 lon: 110.33333 facility: Local Institution - 0126 city: Cdmx state: Distrito Federal zip: 14080 country: Mexico name: Site 0126 role: CONTACT facility: Local Institution - 0122 city: Ciudad de México state: Distrito Federal zip: 03100 country: Mexico name: Site 0122 role: CONTACT lat: 19.42847 lon: -99.12766 facility: Local Institution - 0121 city: Mexico City state: Distrito Federal zip: 14080 country: Mexico name: Site 0121 role: CONTACT lat: 19.42847 lon: -99.12766 facility: Local Institution - 0128 city: México state: Distrito Federal zip: 06720 country: Mexico name: Site 0128 role: CONTACT lat: 19.42847 lon: -99.12766 facility: Local Institution - 0127 city: Morelia state: Michoacán zip: 58260 country: Mexico name: Site 0127 role: CONTACT lat: 19.70078 lon: -101.18443 facility: Local Institution - 0139 city: Monterrey state: Nuevo León zip: 66460 country: Mexico name: Site 0139 role: CONTACT lat: 25.67507 lon: -100.31847 facility: Local Institution - 0125 city: Oaxaca de Juarez state: Oaxaca zip: 68020 country: Mexico name: Site 0125 role: CONTACT lat: 17.06542 lon: -96.72365 facility: Local Institution - 0444 city: Hermosillo state: Sonora zip: 83106 country: Mexico name: Site 0444 role: CONTACT lat: 29.1026 lon: -110.97732 facility: Local Institution - 0463 city: Hermosillo state: Sonora zip: 83106 country: Mexico lat: 29.1026 lon: -110.97732 facility: Local Institution - 0123 city: Huixquilucan zip: 52787 country: Mexico name: Site 0123 role: CONTACT lat: 19.35985 lon: -99.35016 facility: Local Institution - 0124 city: Puebla zip: 72424 country: Mexico name: Site 0124 role: CONTACT lat: 19.03793 lon: -98.20346 facility: Local Institution - 0367 city: Dunedin state: Otago zip: 9016 country: New Zealand name: Site 0367 role: CONTACT lat: -45.87416 lon: 170.50361 facility: Local Institution - 0366 city: Hamilton state: Waikato zip: 3240 country: New Zealand name: Site 0366 role: CONTACT lat: -37.78333 lon: 175.28333 facility: Local Institution - 0391 city: Oslo zip: 0310 country: Norway name: Site 0391 role: CONTACT lat: 59.91273 lon: 10.74609 facility: Local Institution - 0336 city: Bydgoszcz state: Kujawsko-pomorskie zip: 85-168 country: Poland name: Site 0336 role: CONTACT lat: 53.1235 lon: 18.00762 facility: Local Institution - 0337 city: Lublin state: Lubelskie zip: 20-090 country: Poland name: Site 0337 role: CONTACT lat: 51.25 lon: 22.56667 facility: Local Institution - 0443 city: Warszawa state: Mazowieckie zip: 02-781 country: Poland name: Site 0443 role: CONTACT lat: 52.22977 lon: 21.01178 facility: Local Institution - 0201 city: Kraków state: Małopolskie zip: 30-727 country: Poland name: Site 0201 role: CONTACT lat: 50.06143 lon: 19.93658 facility: Local Institution - 0388 city: Poznan state: Wielkopolskie zip: 60-175 country: Poland name: Site 0388 role: CONTACT lat: 52.40692 lon: 16.92993 facility: Local Institution - 0330 city: Katowice state: Śląskie zip: 40-027 country: Poland name: Site 0330 role: CONTACT lat: 50.25841 lon: 19.02754 facility: Local Institution - 0286 city: Lisboa zip: 1500-650 country: Portugal name: Site 0286 role: CONTACT lat: 38.71667 lon: -9.13333 facility: Local Institution - 0098 city: Porto zip: 4200-072 country: Portugal name: Site 0098 role: CONTACT lat: 41.14961 lon: -8.61099 facility: Local Institution - 0372 city: San Juan zip: 00909 country: Puerto Rico name: Site 0372 role: CONTACT lat: 18.46633 lon: -66.10572 facility: Local Institution - 0375 city: Bucuresti state: București zip: 022328 country: Romania name: Site 0375 role: CONTACT lat: 44.42802 lon: 26.09665 facility: Local Institution - 0381 city: Bucuresti state: București zip: 022328 country: Romania name: Site 0381 role: CONTACT lat: 44.42802 lon: 26.09665 facility: Local Institution - 0417 city: Tg.Mures state: Mureș zip: 540136 country: Romania name: Site 0417 role: CONTACT facility: Local Institution - 0380 city: Brasov zip: 500052 country: Romania name: Site 0380 role: CONTACT lat: 45.64861 lon: 25.60613 facility: Local Institution - 0374 city: București zip: 022238 country: Romania name: Site 0374 role: CONTACT lat: 44.42802 lon: 26.09665 facility: Local Institution - 0377 city: București zip: 030171 country: Romania name: Site 0377 role: CONTACT lat: 44.42802 lon: 26.09665 facility: Local Institution - 0382 city: București zip: 030171 country: Romania name: Site 0382 role: CONTACT lat: 44.42802 lon: 26.09665 facility: Local Institution - 0378 city: București zip: 050098 country: Romania name: Site 0378 role: CONTACT lat: 44.42802 lon: 26.09665 facility: Local Institution - 0423 city: Cluj zip: 400015 country: Romania name: Site 0423 role: CONTACT lat: 46.76667 lon: 23.6 facility: Local Institution - 0379 city: Iași zip: 700483 country: Romania name: Site 0379 role: CONTACT lat: 47.16667 lon: 27.6 facility: Local Institution - 0376 city: Sibiu zip: 550245 country: Romania name: Site 0376 role: CONTACT lat: 45.8 lon: 24.15 facility: Local Institution - 0439 city: Dammam state: Ash Sharqīyah zip: 31444 country: Saudi Arabia name: Site 0439 role: CONTACT lat: 26.43442 lon: 50.10326 facility: Local Institution - 0416 city: Riyadh zip: 12713 country: Saudi Arabia name: Site 0416 role: CONTACT lat: 24.68773 lon: 46.72185 facility: Local Institution - 0427 city: Singapore state: Central Singapore zip: 169608 country: Singapore name: Site 0427 role: CONTACT lat: 1.28967 lon: 103.85007 facility: Local Institution - 0355 city: Banska Bystrica state: Banskobystrický Kraj zip: 97517 country: Slovakia name: Site 0355 role: CONTACT lat: 48.73946 lon: 19.15349 facility: Local Institution - 0204 city: Bratislava zip: 83101 country: Slovakia name: Site 0204 role: CONTACT lat: 48.14816 lon: 17.10674 facility: Local Institution - 0412 city: A Coruña state: A Coruña [La Coruña] zip: 15006 country: Spain name: Site 0412 role: CONTACT lat: 43.37135 lon: -8.396 facility: Local Institution - 0071 city: L'Hospitalet Del Llobregat state: Barcelona [Barcelona] zip: 08908 country: Spain name: Site 0071 role: CONTACT facility: Local Institution - 0389 city: Barakaldo state: Bizkaia zip: 48903 country: Spain name: Site 0389 role: CONTACT lat: 43.29639 lon: -2.98813 facility: Local Institution - 0172 city: Santa Cruz de Tenerife state: Canarias zip: 38010 country: Spain name: Site 0172 role: CONTACT lat: 28.46824 lon: -16.25462 facility: Local Institution - 0314 city: San Sebastian state: Gipuzkoa zip: 20014 country: Spain name: Site 0314 role: CONTACT lat: 43.31283 lon: -1.97499 facility: Local Institution - 0096 city: Majadahonda state: Madrid, Comunidad De zip: 28222 country: Spain name: Site 0096 role: CONTACT lat: 40.47353 lon: -3.87182 facility: Local Institution - 0409 city: El Palmar, Murcia state: Murcia, Región De zip: 30120 country: Spain name: Site 0409 role: CONTACT facility: Local Institution - 0092 city: Malaga state: Málaga zip: 29010 country: Spain name: Site 0092 role: CONTACT lat: 36.72016 lon: -4.42034 facility: Local Institution - 0095 city: Cáceres zip: 10003 country: Spain name: Site 0095 role: CONTACT lat: 39.47649 lon: -6.37224 facility: Local Institution - 0072 city: Madrid zip: 28006 country: Spain name: Site 0072 role: CONTACT lat: 40.4165 lon: -3.70256 facility: Local Institution - 0093 city: Salamanca zip: 37007 country: Spain name: Site 0093 role: CONTACT lat: 40.96882 lon: -5.66388 facility: Local Institution - 0277 city: Uppsala state: Uppsala Län [se-03] zip: 751 85 country: Sweden name: Site 0277 role: CONTACT lat: 59.85882 lon: 17.63889 facility: Local Institution - 0278 city: Linköping state: Östergötlands Län [se-05] zip: 581 85 country: Sweden name: Site 0278 role: CONTACT lat: 58.41086 lon: 15.62157 facility: Local Institution - 0142 city: Chiayi City state: Chiayi zip: 613 country: Taiwan name: Site 0142 role: CONTACT lat: 23.47917 lon: 120.44889 facility: Local Institution - 0146 city: Tainan City state: Tainan zip: 71004 country: Taiwan name: Site 0146 role: CONTACT lat: 22.99083 lon: 120.21333 facility: Local Institution - 0159 city: Kaohsiung zip: 83301 country: Taiwan name: Site 0159 role: CONTACT lat: 22.61626 lon: 120.31333 facility: Local Institution - 0135 city: Taichung zip: 40447 country: Taiwan name: Site 0135 role: CONTACT lat: 24.1469 lon: 120.6839 facility: Local Institution - 0145 city: Taichung zip: 407 country: Taiwan name: Site 0145 role: CONTACT lat: 24.1469 lon: 120.6839 facility: Local Institution - 0134 city: Taipei zip: 10002 country: Taiwan name: Site 0134 role: CONTACT lat: 25.04776 lon: 121.53185 facility: Local Institution - 0147 city: Taipei zip: 112 country: Taiwan name: Site 0147 role: CONTACT lat: 25.04776 lon: 121.53185 facility: Local Institution - 0158 city: Taoyuan zip: 333 country: Taiwan name: Site 0158 role: CONTACT lat: 24.95233 lon: 121.20193 facility: Local Institution - 0434 city: Bangkok state: Krung Thep Maha Nakhon zip: 10330 country: Thailand name: Site 0434 role: CONTACT lat: 13.75398 lon: 100.50144 facility: Local Institution - 0426 city: Bangkok state: Krung Thep Maha Nakhon zip: 10700 country: Thailand name: Site 0426 role: CONTACT lat: 13.75398 lon: 100.50144 facility: Local Institution - 0428 city: Chiang Mai zip: 50200 country: Thailand name: Site 0428 role: CONTACT lat: 18.79038 lon: 98.98468 facility: Local Institution - 0400 city: Ankara zip: 06100 country: Turkey name: Site 0400 role: CONTACT lat: 39.91987 lon: 32.85427 facility: Local Institution - 0405 city: Ankara zip: 06100 country: Turkey name: Site 0405 role: CONTACT lat: 39.91987 lon: 32.85427 facility: Local Institution - 0422 city: Ankara zip: 06170 country: Turkey name: Site 0422 role: CONTACT lat: 39.91987 lon: 32.85427 facility: Local Institution - 0401 city: Ankara zip: 06200 country: Turkey name: Site 0401 role: CONTACT lat: 39.91987 lon: 32.85427 facility: Local Institution - 0406 city: İzmir zip: 35100 country: Turkey name: Site 0406 role: CONTACT lat: 38.41273 lon: 27.13838 facility: Local Institution - 0403 city: Mersin zip: 33343 country: Turkey name: Site 0403 role: CONTACT lat: 36.79526 lon: 34.61792 facility: Local Institution - 0407 city: Samsun zip: 55270 country: Turkey name: Site 0407 role: CONTACT lat: 41.27976 lon: 36.3361 facility: Local Institution - 0402 city: Trabzon zip: 61080 country: Turkey name: Site 0402 role: CONTACT lat: 41.005 lon: 39.72694 hasResults: False
<\|newrecord\|> nctId: NCT06356116 id: CMUH111-REC3-029 briefTitle: Rehabilitation After Direct Anterior Approach for Total Hip Arthroplasty overallStatus: RECRUITING date: 2023-11-14 date: 2024-10-31 date: 2024-12-31 date: 2024-04-10 date: 2024-04-11 name: China Medical University Hospital class: OTHER briefSummary: The causes for total hip arthroplasty (THA) in Taiwan include ischemic necrosis of the femoral head and degenerative osteoarthritis. Contemporary, the surgical approach for total hip replacement mostly adopts the lateral approach. However, the direct anterior approach (DAA) has gained attention gradually due to its characteristics such as muscle preservation, small surgical incision length, and few surgical complications. Nevertheless, literature lacks detailed exploration or long-term follow-up on the recovery of physical functions related to fall occurrence after this type of surgery. It limits the establishment and design of suitable post-operative rehabilitation plans. Therefore, this study aims to explore and follow-up the functional recovery in patients who undergo the DAA for hip replacement using current usual care and new-designed accelerated rehabilitation program. The proposed method involves recruiting 30 patients who will undergo the DAA for total hip replacement, who will receive the current usual care plan; and another 30 patients will receive the accelerated rehabilitation program. The assessments will be conducted before the surgery and at 2, 4, 8, and 12 weeks after the operation, evaluating hip joint function, hip abduction and flexion muscle strength, balance function, and gait performance. The statistical analysis will utilize mixed-model two-factor ANOVA, comparing the preoperative and postoperative recovery of patients undergoing the DAA with different intervention programs and at different time points. The expected outcome of this study is to enhance the understanding of the functional recovery of patients undergoing the DAA for total hip replacement in terms of hip joint function, muscle strength, balance function, and gait performance after surgery. This information will help establish the targeted DAA postoperative treatment plans, which will be practically applied to patients and compared with the current usual care to assess its effectiveness, ultimately contributing to more efficient rehabilitation plans in the future. conditions: Total Hip Arthroplasty studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 60 type: ESTIMATED name: Usual care name: Accelerated rehabilitation measure: Functional recovery questionaire measure: Maximum muscle strength measure: Quality of Life questionaire measure: Balance function measure: Gait performance measure: Walking speed sex: ALL minimumAge: 25 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: China Medical University Hospital status: RECRUITING city: Taichung zip: 404 country: Taiwan name: Hsiu-Chen Lin, PhD role: CONTACT phone: +886-4-22053366 phoneExt: 7303 email: hclin@mail.cmu.edu.tw lat: 24.1469 lon: 120.6839 hasResults: False
<\|newrecord\|> nctId: NCT06356103 id: 0107060 briefTitle: Efficacy Of High Caloric Whey-Based Partially Hydrolyzed Formula On Undernourished Neurologically Impaired Children overallStatus: COMPLETED date: 2022-06-01 date: 2022-12-31 date: 2023-07-15 date: 2024-04-10 date: 2024-04-10 name: Alexandria University class: OTHER briefSummary: Purpose: Undernutrition is common in neurologically impaired children. It increases the burden of comorbidities and affects the quality of life of these children. It must be recognized and treated as early as possible. This study aimed primarily to compare the efficacy of high-caloric whey-based partially hydrolyzed formula (HC-WPHF) versus standard feeding on the nutritional status reflected by growth parameters and feeding tolerance in undernourished children with neurological impairment (NI). The secondary aim was to compare the change in these parameters after using HC-WPHF for 3 and 6 months. conditions: Nutrition Disorder, Child conditions: Neurologic Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A Randomized Controlled Study primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 100 type: ACTUAL name: High Caloric Whey-Based Partially Hydrolyzed Formula name: nutritional feeding according to ESPGHAN guidelines measure: To compare the efficacy of high-caloric whey-based partially hydrolyzed formula versus standard feeding on the weight in kilogram in undernourished children with neurological impairment (NI). measure: To compare the efficacy of high-caloric whey-based partially hydrolyzed formula versus standard feeding on the height/length in centimeter in undernourished children with neurological impairment (NI). measure: To compare the efficacy of high-caloric whey-based partially hydrolyzed formula versus standard feeding on the body mass index (BMI) in children with neurological impairment (NI). measure: To compare the efficacy of high-caloric whey-based partially hydrolyzed formula versus standard feeding on the head circumference in centimeter in undernourished children with neurological impairment (NI) measure: To follow up the efficacy of high-caloric whey-based partially hydrolyzed formula versus standard feeding on the weight in kilogram in undernourished children with neurological impairment (NI) for 3 and 6 months measure: To follow up the efficacy of high-caloric whey-based partially hydrolyzed formula versus standard feeding on the height/length in Centimeter in undernourished children with neurological impairment (NI) for 3 and 6 months measure: To follow up the efficacy of high-caloric whey-based partially hydrolyzed formula versus on the body mass index in undernourished children with neurological impairment (NI) for 3 and 6 months measure: To follow up the efficacy of high-caloric whey-based partially hydrolyzed formula versus standard feeding on the head circumference in Centimeter in undernourished children with neurological impairment (NI) for 3 and 6 months sex: ALL minimumAge: 2 Years maximumAge: 6 Years stdAges: CHILD facility: Alexandria University Children Hospital city: Alexandria zip: 23445 country: Egypt lat: 31.21564 lon: 29.95527 hasResults: False
<\|newrecord\|> nctId: NCT06356090 id: 2023.0322 - NL84369.018.23 briefTitle: SPACE: a Parent-based Treatment for Pediatric OCD overallStatus: RECRUITING date: 2023-11-23 date: 2025-03-31 date: 2025-03-31 date: 2024-04-10 date: 2024-04-10 name: Chaim Huijser class: OTHER name: Levvel briefSummary: This study will investigate the parent-based treatment SPACE: Supportive Parenting for Anxious Childhood Emotions. The aim of this study is to investigate whether SPACE is effective in reducing family accommodation (FA) and OCD symptoms in children with a complex obsessive-compulsive disorder (OCD), that did not or cannot benefit from first line treatment. conditions: Obsessive-Compulsive Disorder conditions: Obsessive-Compulsive Disorder in Children conditions: Obsessive-Compulsive Disorder in Adolescence conditions: Anxiety Disorders and Symptoms studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Single case experimental design (SCED) with multiple baselines primaryPurpose: TREATMENT masking: NONE count: 25 type: ESTIMATED name: Supportive Parenting for Anxious Childhood Emotions (SPACE) measure: (Change in) OCD severity measure: (Change in) family accommodation (parent report) measure: (Change in) Family accommodation (child report) measure: Daily (change in) OCD symptoms measure: Daily (change in) family accommodation measure: Symptoms of child anxiety measure: Symptoms of child depression measure: Symptoms of autism measure: Quality of life (parent-report) measure: Quality of life (child-report) measure: Clinical impression of outcome measure: Treatment progress measure: Session experience measure: Treatment adherence measure: Demographic variables measure: Psychiatric DSM-5 diagnosis of the child measure: Parenting burden measure: Psychopathology and adaptive functioning of parents measure: Child Behavior Checklist (CBCL, parent-report) measure: Youth Self-report (YSR) (child-report) measure: Teacher Report Form Emotional- and behavioral problems of the child (teacher- report) measure: Treatment satisfaction sex: ALL minimumAge: 7 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Amsterdam UMC / Levvel (Academic centre for child & adolescent psychiatry) status: RECRUITING city: Amsterdam country: Netherlands name: J.D.K. Veeger role: CONTACT name: C. Huijser, Dr. role: PRINCIPAL_INVESTIGATOR lat: 52.37403 lon: 4.88969 hasResults: False
<\|newrecord\|> nctId: NCT06356077 id: OBPM_HTN2024 briefTitle: Evaluation of the Satisfaction of a Hypertensive Population in Their Use of the Aktiia 24/7 Blood Pressure Monitor acronym: OBPM_HTN2024 overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2027-12 date: 2027-12 date: 2024-04-10 date: 2024-04-10 name: Aktiia SA class: INDUSTRY briefSummary: OBPM_HTN2024 study was designed by AKTIIA SA to evaluate how a hypertensive population, reflective of the United States and encompassing a range of phenotypes, perceives the Aktiia 24/7 device (Aktiia G1) during their first 3 months of use. conditions: Hypertension studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 5000 type: ESTIMATED measure: Preferences of subjects regarding the method to monitor their blood pressure between Aktiia Bracelet, Home Blood Pressure Monitor, or Ambulatory Blood Pressure Monitor measure: Frequency of Aktiia app use measure: Frequency of use of Aktiia device as compared to previously use other blood pressure monitors measure: Evaluation of subject's experience in using the Aktiia App measure: Evaluation of the most valuable data on the Aktiia Mobile App by subjects sex: ALL minimumAge: 21 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06356064 id: E2-23-3834 briefTitle: Radial or Focus Extracorporeal Shock Wave Therapy in Epin Calcanei overallStatus: COMPLETED date: 2023-05-15 date: 2023-12-15 date: 2024-01-15 date: 2024-04-10 date: 2024-04-22 name: Ankara City Hospital Bilkent class: OTHER briefSummary: Objective: The aim of the study was to investigate the effectiveness of radial and focused ESWT treatment on pain, function, and size of the calcaneal spur in patients with a clinical and radiological diagnosis of epin calcanei.
Methods: A total of 112 patients aged between 18 and 95 years were randomly divided into two groups: group 1 received rESWT (2.4 bar 12 hz 2000 beats), and group 2 received fESWT (0.14 bar 14 hz 1000 beats) three times a week for three weeks. All patients were evaluated using the Visual Analog Scale (VAS)-pain and Foot Function Index (FFI) before and after the treatment, at 4 weeks and 12 weeks. Epin size was measured radiographically in the patients before and after the treatment at the 12-week follow-up. conditions: Spur, Heel studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 112 type: ACTUAL name: Extracorporeal shock wave therapy measure: Visual Analog Scale measure: Functional Foot Index measure: Radiographic assesment, epin size sex: ALL minimumAge: 18 Years maximumAge: 95 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Özge TEZEN city: Ankara country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.